0001683168-18-003390.txt : 20181114 0001683168-18-003390.hdr.sgml : 20181114 20181114070608 ACCESSION NUMBER: 0001683168-18-003390 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 40 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181114 DATE AS OF CHANGE: 20181114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RXi Pharmaceuticals Corp CENTRAL INDEX KEY: 0001533040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36304 FILM NUMBER: 181180398 BUSINESS ADDRESS: STREET 1: 257 SIMARANO DRIVE STREET 2: SUITE 101 CITY: MARLBOROUGH STATE: MA ZIP: 01752 BUSINESS PHONE: (508) 767-3861 MAIL ADDRESS: STREET 1: 257 SIMARANO DRIVE STREET 2: SUITE 101 CITY: MARLBOROUGH STATE: MA ZIP: 01752 10-Q 1 rxi_10q-093018.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-36304

RXi Pharmaceuticals Corporation

(Exact name of registrant as specified in its charter)

Delaware

45-3215903

(State of incorporation)

(I.R.S. Employer

Identification No.)

257 Simarano Drive, Suite 101, Marlborough, MA 01752

(Address of principal executive office) (Zip code)

Registrant’s telephone number: (508) 767-3861

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter time that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 9, 2018, RXi Pharmaceuticals Corporation had 18,164,356 shares of common stock, $0.0001 par value, outstanding.

RXI PHARMACEUTICALS CORPORATION

FORM 10-Q — QUARTER ENDED SEPTEMBER 30, 2018

INDEX

Part No.	Item No.	Description	Page No.

I		FINANCIAL INFORMATION

	1	Financial Statements (Unaudited)		3
		Condensed Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017		3
		Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2018 and 2017		4
		Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2018 and 2017		5
		Notes to Condensed Consolidated Financial Statements		6
	2	Management’s Discussion and Analysis of Financial Condition and Results of Operations		13
	3	Quantitative and Qualitative Disclosures about Market Risk		20
	4	Controls and Procedures		20

II		OTHER INFORMATION		21

	1	Legal Proceedings		21
	1A	Risk Factors		21
	2	Unregistered Sales of Equity Securities and Use of Proceeds		21
	3	Defaults Upon Senior Securities		21
	4	Mine Safety Disclosures		21
	5	Other Information		21
	6	Exhibits		22


Signatures				23

PART I — FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

RXI PHARMACEUTICALS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share and per share data)

(Unaudited)

	September 30, 2018			December 31, 2017
ASSETS
Current assets:
Cash and cash equivalents	$	3,240		$	3,581
Restricted cash		50			50
Prepaid expenses and other current assets		332			201
Total current assets		3,622			3,832
Property and equipment, net		187			248
Other assets		–			18
Total assets	$	3,809		$	4,098

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	491		$	511
Accrued expenses		1,568			1,754
Total current liabilities		2,059			2,265
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding		–			–
Common stock, $0.0001 par value, 100,000,000 shares authorized; 4,449,909 and 2,429,993 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively		–			–
Additional paid-in capital		85,934			80,384
Accumulated deficit		(84,184	)		(78,551	)
Total stockholders’ equity		1,750			1,833
Total liabilities and stockholders’ equity	$	3,809		$	4,098

The accompanying notes are an integral part of these condensed consolidated financial statements.

RXI PHARMACEUTICALS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except share and per share data)

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Revenues	$	57		$	–		$	138		$	–
Operating expenses:
Research and development		838			1,490			3,382			4,166
Acquired in-process research and development		–			–			–			4,696
General and administrative		711			986			2,386			3,209
Total operating expenses		1,549			2,476			5,768			12,071
Operating loss		(1,492	)		(2,476	)		(5,630	)		(12,071	)
Total other expense, net		(1	)		–			(3	)		–
Loss before income taxes		(1,493	)		(2,476	)		(5,633	)		(12,071	)
Income tax benefit		–			–			–			1,621
Net loss	$	(1,493	)	$	(2,476	)	$	(5,633	)	$	(10,450	)
Net loss per share:
Basic and diluted	$	(0.34	)	$	(1.05	)	$	(1.54	)	$	(4.71	)
Weighted average shares used in calculating:
Basic and diluted net loss per share		4,371,259			2,351,144			3,662,924			2,216,775

The accompanying notes are an integral part of these condensed consolidated financial statements.

RXI PHARMACEUTICALS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands)
(Unaudited)

	Nine Months Ended September 30,
	2018			2017
Cash flows from operating activities:
Net loss	$	(5,633	)	$	(10,450	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		61			48
Non-cash stock-based compensation		117			276
Acquired in-process research and development		–			4,696
Deferred taxes		–			(1,621	)
Changes in operating assets and liabilities:
Prepaid expenses and other assets		(113	)		(121	)
Accounts payable		(20	)		(417	)
Accrued expenses		(186	)		276
Net cash used in operating activities		(5,774	)		(7,313	)
Cash flows from investing activities:
Cash acquired in MirImmune Inc. acquisition		–			100
Cash paid for purchase of property and equipment		–			(203	)
Net cash used in investing activities		–			(103	)
Cash flows from financing activities:
Net proceeds from the issuance of common stock and warrants		5,433			(74	)
Net cash provided by (used in) financing activities		5,433			(74	)
Net decrease in cash, cash equivalents and restricted cash		(341	)		(7,490	)
Cash, cash equivalents and restricted cash at the beginning of period		3,631			12,956
Cash, cash equivalents and restricted cash at the end of period	$	3,290		$	5,466
Supplemental disclosure of non-cash investing and financing activities:
Conversions of Series B convertible preferred stock into common stock	$	–		$	3,525
Conversion of Series C convertible preferred stock into common stock	$	–		$	816
MirImmune Inc. Acquisition:
Cancellation of notes receivable	$	–		$	150
Accounts payable assumed	$	–		$	5
Fair value of securities issued	$	–		$	2,824

The accompanying notes are an integral part of these condensed consolidated financial statements.

RXI PHARMACEUTICALS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Nature of Operations

RXi Pharmaceuticals Corporation (“RXi,” “we,” “our” or the “Company”) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (“sd-rxRNA^®”) therapeutic platform. The Company’s sd-rxRNA compounds do not require a delivery vehicle to penetrate the cell and are designed to “silence,” or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. We believe that this provides RXi with a distinct advantage in adoptive cell transfer therapy, the Company’s initial focus and approach to immuno-oncology.

Prior to the Company’s acquisition of MirImmune Inc. in January 2017, our principal activities consisted of the preclinical and clinical development of the Company’s sd-rxRNA compounds and topical immunotherapy agent in the areas of dermatology and ophthalmology. In January 2018, after a thorough review of its business operations, development programs and financial resources, the Company made a strategic decision to focus solely on immuno-oncology to accelerate growth and support a potential return on investment for its stockholders. The Company’s current business strategy focuses on the development of immuno-oncology therapeutics utilizing our proprietary sd-rxRNA technology.

The Company intends to seek a partner and/or out-licensee for each of its dermatology and ophthalmology franchises, including RXI-109 and Samcyprone^®, to continue their development. The goal of any such transaction would be to allow the Company to monetize these preclinical and clinical assets to further fund ongoing and future development work in our immuno-oncology programs and extend our financial runway.

On January 3, 2018, the Board of Directors of the Company approved a 1-for-10 reverse stock split of the Company’s outstanding common stock, which was effected on January 8, 2018. All share and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split, including reclassifying an amount equal to the reduction in par value to additional paid-in capital.

2. Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Certain information and footnote disclosures included in the Company’s annual financial statements have been condensed or omitted. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included. Interim results are not necessarily indicative of results for a full year.

Principles of Consolidation

The consolidated financial statements include the accounts of RXi Pharmaceuticals Corporation and its wholly-owned subsidiary, MirImmune, LLC. All material intercompany accounts have been eliminated in consolidation.

Uses of Estimates in Preparation of Financial Statements

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from these estimates.

Cash Equivalents and Restricted Cash

The Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in certificates of deposit.

Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards.

Fair Value of Financial Instruments

The carrying amounts reported in the balance sheet for cash equivalents, restricted cash, accounts payable and accrued expenses approximate their fair values due to their short-term nature.

Research and Development Expenses

Research and development costs relate to salaries, employee benefits, facility-related expenses, supplies, stock-based compensation related to employees and non-employees involved in the Company’s research and development, external services, other operating costs and overhead related to its research and development departments, costs to acquire technology licenses and expenses associated with preclinical activities and its clinical trials. Research and development expenses are charged to expense as incurred. Payments made by the Company in advance for research and development services not yet provided and/or for materials not yet received are recorded as prepaid expenses and expensed when the service has been performed or when the goods have been received. Accrued liabilities are recorded related to those expenses for which vendors have not yet billed the Company with respect to services provided and/or materials that it has received.

Preclinical and clinical trial expenses relate to estimates of costs incurred and fees connected with clinical trial sites, third-party clinical research organizations and other preclinical and clinical related activities and include such items as subject-related fees, laboratory work, investigator fees and analysis costs. Costs associated with these expenses are generally payable on the passage of time or when certain milestones are achieved. Expense is recorded during the period incurred or in the period in which a milestone is achieved. In order to ensure that the Company has adequately provided for preclinical and clinical expenses during the proper period, the Company maintains an accrual to cover these expenses. These accruals are assessed on a quarterly basis and are based on such assumptions as expected total cost, the length of the study, timing of certain milestones and other information available to us. Actual results may differ from these estimates and could have a material impact on the Company’s reported results. The Company’s historical accrual estimates have not been materially different from its actual costs.

Stock-based Compensation

The Company follows the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, “Compensation — Stock Compensation” (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, officers, non-employee directors, and non-employees, including stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period.

Income Taxes

The Company recognizes assets or liabilities for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with the FASB ASC Topic 740, “Accounting for Income Taxes.” On December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act tax reform legislation. This legislation makes significant changes in U.S. tax law including a reduction in the corporate tax rates, changes to net operating loss carryforwards and carrybacks, and a repeal of the corporate alternative minimum tax. The Company is continuing to assess the impact of the Tax Cuts and Jobs Act and does not expect the provisions to have a material impact on the Company’s consolidated financial statements.

Comprehensive Loss

The Company’s comprehensive loss is equal to its net loss for all periods presented.

Net Loss per Share

The Company accounts for and discloses net loss per share in accordance with the FASB ASC Topic 260, “Earnings per Share.” Basic and diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares.

3. Recent Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. On July 9, 2015, the FASB voted to delay the effective date of the new revenue standard by one year but to permit entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU 2016-08, “Revenue from Contracts with Customers (Topic 606) – Principal Versus Agent Considerations,” which improves the operability and understandability of the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606) – Identifying Performance Obligations and Licensing,” which clarifies two aspects of the guidance on accounting for revenue contracts with customers: identifying performance obligations and the licensing implementation guidance. In May 2016, the FASB issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606) – Narrow Scope Improvements and Practical Expedients,” which addresses collectability assessment, presentation of sales taxes, noncash consideration and completed contracts and contract modifications at transition. The amendments in these ASUs do not change the core principles for those areas. This standard became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is not permitted. The Company adopted this ASU in the first quarter of 2018. Since the Company has no significant revenue, this ASU had no immediate impact on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842),” which requires companies that are lessees to recognize a right-of-use asset and lease liability for most leases that do not meet the definition of a short-term lease. For income statement purposes, leases will continue to be classified as either operating or financing. Classification will be based on criteria that are largely similar to those applied in current lease accounting. This standard will result in extensive qualitative and quantitative disclosure changes. In July 2018, the FASB issued ASU 2018-10, “Codification Improvements to Topic 842, Leases,” which affects narrow aspects of the guidance issued in the amendments in ASU 2016-02, “Leases.” The FASB further issued ASU 2018-11, “Leases (Topic 842): Targeted Improvements”, in July 2018, which provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption consistent with preparers’ requests. This standard will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. The Company is currently evaluating the impact of this ASU on its consolidated financial statements, but expects that the adoption will result in the current operating lease being recorded on the consolidated balance sheet.

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718) – Improvements to Nonemployee Share-Based Payment Accounting,” which expands the scope of ASC 718 to include share-based payment transactions for acquiring goods and services from non-employees. The amendment specifies that ASC 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. This standard will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company early adopted this ASU in the second quarter of 2018. The ASU had no material impact on the Company’s consolidated financial statements.

In August 2018, the Securities and Exchange Commission issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to the Company’s financial reporting will be the inclusion of the annual disclosure requirement of changes in stockholders’ equity in Rule 3-04 of Regulation S-X to interim periods. We will adopt this new rule beginning with our financial reporting for the quarter ended March 31, 2019. Upon adoption, the Company will include the consolidated Statements of Stockholders’ Equity with each quarterly filing on Form 10-Q.

4. Stockholders’ Equity

Lincoln Park Capital Fund, LLC – On August 8, 2017, the Company entered into a purchase agreement (the “LPC Purchase Agreement”) and a registration rights agreement with LPC, pursuant to which the Company has the right to sell to LPC shares of the Company’s common stock, subject to certain limitations and conditions set forth in the LPC Purchase Agreement.

During the three months ended September 30, 2018, the Company sold 15,000 shares of common stock to LPC for net proceeds of approximately $21,000. During the nine months ended September 30, 2018, the Company sold 435,000 shares of common stock to LPC for net proceeds of approximately $1,312,000.

April 2018 Registered Direct Offering and Private Placement – On April 11, 2018, the Company closed a registered direct offering of 1,510,604 shares of the Company’s common stock at a purchase price of $3.15 per share (the “April 2018 Offering”) pursuant to the Securities Purchase Agreement dated as of April 9, 2018, by and among the Company and each purchaser identified on the signature pages thereto. In a concurrent private placement, the Company sold warrants (the “Warrants”) to purchase a total of 1,132,953 shares of common stock at a purchase price of $0.125 per underlying warrant share and with an exercise price of $3.15 per share (the “Private Placement”). In connection with the April 2018 Offering and Private Placement, the Company issued warrants to purchase a total of 75,530 shares of common stock with an exercise price of $4.0546 per share to the placement agent, H.C. Wainwright & Co., LLC (the “Placement Agent Warrants”). Assuming the Warrants and Placement Agent Warrants are not exercised, net proceeds to the Company from the April 2018 Offering and Private Placement were $4,210,000 after deducting placement agent fees and offering expenses paid by the Company.

The Company assessed the Warrants and Placement Agent Warrants under the FASB ASC Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”) and determined that the Warrants and Placement Agent Warrants were outside the scope of ASC 480. The Company next assessed the Warrants and Placement Agent Warrants under the FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). Under the related guidance, a reporting entity shall not consider a contract to be a derivative instrument if the contract is both (1) indexed to the entity’s own stock and (2) classified in stockholders’ equity. The Company determined that the Warrants and Placement Agent Warrants were indexed to the Company’s stock, as the agreements do not contain any exercise contingencies and the settlement amount equals the difference between the fair value of the Company’s common stock price and the strike price. The Company also assessed the classification in stockholders’ equity and determined the Warrants and Placement Agent Warrants met all of the criteria for classification as equity under ASC 815. Based on this analysis, the Company determined that the Warrants and Placement Agent Warrants would be classified in stockholders’ equity.

Warrants — The following table summarizes the Company’s outstanding equity-classified warrants at September 30, 2018:

Exercise price		Number of Shares Underlying Warrants		Expiration
$	52.00		130,007		June 2, 2020
$	9.00		1,277,793		December 21, 2021
$	3.15		1,132,953		May 31, 2023
$	4.0546		75,530		April 9, 2023
	Total warrants outstanding		2,616,283

5. Net Loss per Share

The following table sets forth the potential common shares excluded from the calculation of net loss per share because their inclusion would be anti-dilutive:

	September 30,
	2018		2017
Options to purchase common stock		157,514		53,100
Unvested, restricted stock		73,587		–
Restricted stock units		151,250		–
Warrants to purchase common stock		2,616,283		1,408,000
Total		2,998,634		1,461,100

6. Stock-based Compensation

Stock Options

The Company uses the Black-Scholes option-pricing model to determine the fair value of all its option grants. For valuing options granted during the three and nine months ended September 30, 2018 and 2017, the following assumptions were used:

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2018			2017			2018			2017
Risk-free interest rate		2.93	%		1.94 – 2.35	%		2.70 – 2.93	%		1.73 – 2.49	%
Expected volatility		161.45	%		83.87 – 91.99	%		91.28 – 161.45	%		82.99 – 123.01	%
Weighted average expected volatility		161.45	%		87.93	%		159.55	%		84.65	%
Expected lives (in years)		6.25			6.25 – 10.00			5.50 – 10.00			5.20 – 10.00
Expected dividend yield		0.00	%		0.00	%		0.00	%		0.00	%

The weighted average fair value of options granted during the three months ended September 30, 2018 and 2017 was $1.72 and $4.90, respectively. The weighted average fair value of options granted during the nine months ended September 30, 2018 and 2017 was $1.75 and $4.90, respectively.

The risk-free interest rate used for each grant is based upon the yield on zero-coupon U.S. Treasury securities with a term similar to the expected life of the related option. The Company’s expected stock price volatility assumption is based upon the Company’s own implied volatility. The expected life assumption for option grants is based upon the simplified method provided for under ASC 718. The dividend yield assumption is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends.

The following table summarizes the activity of the Company’s stock options for the nine months ended September 30, 2018:

	Number of Shares			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
Balance at December 31, 2017		50,180		$	192.30
Granted		108,250			1.83
Exercised		–			–
Cancelled		(916	)		29.50
Balance at September 30, 2018		157,514		$	62.35	$	–
Exercisable at September 30, 2018		38,939		$	244.14	$	–

Stock-based compensation expense related to stock options for the three months ended September 30, 2018 and 2017 was $17,000 and $43,000, respectively.

Stock-based compensation expense related to stock options for the nine months ended September 30, 2018 and 2017 was $95,000 and $276,000, respectively.

Restricted Stock Units

In addition to options to purchase shares of common stock, the Company may also grant restricted stock units (“RSUs”). RSUs are generally subject to graded vesting and the satisfaction of service requirements, similar to our stock options. Upon vesting, each outstanding RSU will be exchanged for one share of the Company’s common stock. The fair value of the RSUs awarded are based on the Company’s closing stock price at the grant date and are expensed over the requisite service period.

The following table summarizes the activity of the Company’s RSUs for the nine months ended September 30, 2018:

	Number of Shares		Weighted- Average Grant Date Fair Value Per Share
Unvested units at December 31, 2017		–	$	–
Granted		151,250		1.79
Vested		–		–
Forfeited		–		–
Unvested units at September 30, 2018		151,250	$	1.79

During the three and nine months ended September 30, 2018, the Company recorded $22,000 of expense related to RSUs. There was no expense related to RSUs recorded in the same prior year periods. Such expense is included in stock-based compensation expense in the condensed consolidated statement of operations.

Restricted Stock

On August 31, 2018, Geert Cauwenbergh, Dr. Med. Sc., the Company’s Chief Executive Officer, elected the right to receive, in lieu of cash, for the period from September 15, 2018 to December 31, 2018, up to 50% of his base salary and cash bonuses, if any, (collectively, the “Compensation”) payable in the form of unvested, restricted shares of the Company’s common stock. Such restricted shares will be received in the form of a series of grants made on each Company payroll date in lieu of cash payment of the Compensation and shall vest in full on January 1, 2019, subject to his continued employment through such date. The fair value of the restricted stock is based on the Company’s closing stock price on the date of grant and is expensed over the vesting period.

For the three and nine months ended September 30, 2018, the Company granted 73,587 restricted shares of the Company’s common stock in lieu of Compensation to Dr. Cauwenbergh. No stock-based compensation expense was recorded related to the restricted shares for the three and nine months ended September 30, 2018 or 2017. Stock-based compensation expense based on the grant date fair value of the restricted shares will be recognized as an expense over the requisite vesting period, which is expected to occur during the three months ended December 31, 2018.

Compensation Expense Related to Equity Awards

The Company recorded total stock-based compensation expense related to equity awards in the condensed consolidated statement of operations for the three and nine months ended September 30, 2018 and 2017 as follows, in thousands:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2018		2017		2018		2017
Research and development	$	9	$	7	$	29	$	80
General and administrative		30		36		88		196
Total stock-based compensation	$	39	$	43	$	117	$	276

7. Subsequent Events

On October 3, 2018, the Company closed an underwritten public offering (the “October 2018 Offering”) of (i) 3,725,714 units (the “Units”), at a public offering price of $0.70 per Unit, with each Unit consisting of one share of common stock and one warrant (the “October 2018 Warrants”) to purchase one share of common stock and (ii) 17,702,858 pre-funded units (the “Pre-Funded Units”), at a public offering price of $0.69 per Pre-Funded Unit, with each Pre-Funded Unit consisting of one pre-funded warrant (the “Pre-Funded Warrants”) to purchase one share of common stock and one October 2018 Warrant. The October 2018 Warrants included in the Units and Pre-Funded Units are immediately exercisable at a price of $0.70 per share and expire seven years from the date of issuance. The Pre-Funded Warrants included in the Pre-Funded Units are immediately exercisable at a price per share of $0.01 and do not expire. The Company is currently reviewing the accounting for the Pre-Funded Warrants and Warrants issued in the October 2018 Offering. Assuming the October 2018 Warrants are not exercised, net proceeds from the October 2018 Offering were approximately $13,300,000 after deducting underwriting discounts and commissions and offering expenses paid by the Company.

The net proceeds from the October 2018 Offering will be reflected in stockholders’ equity for the year ending December 31, 2018.

Additionally, pursuant to the October 2018 Offering, the Company issued warrants to purchase up to 1,607,143 shares of common stock at an exercise price of $0.875 per share to the underwriter, H.C. Wainwright & Co., LLC.

Subsequent to the balance sheet date, 10,534,286 Pre-Funded Warrants were converted into 10,534,286 shares of common stock for net proceeds of $105,000.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

In this document, “we,” “our,” “ours,” “us,” “RXi” and the “Company” refers to RXi Pharmaceuticals Corporation and our subsidiary, MirImmune, LLC and the ongoing business operations of RXi Pharmaceuticals Corporation and MirImmune, LLC, whether conducted through RXi Pharmaceuticals Corporation or MirImmune, LLC.

This management’s discussion and analysis of financial condition as of September 30, 2018 and results of operations for the three and nine months ended September 30, 2018 and 2017 should be read in conjunction with the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the Securities and Exchange Commission on March 26, 2018.

This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “intends,” “believes,” “anticipates,” “indicates,” “plans,” “expects,” “suggests,” “may,” “should,” “potential,” “designed to,” “will” and similar references, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including those identified in our Annual Report on Form 10-K for the year ended December 31, 2017 under the heading “Risk Factors” and in other filings the Company periodically makes with the Securities and Exchange Commission. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q speak as of the date hereof and the Company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this report.

Overview

RXi Pharmaceuticals Corporation is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (“sd-rxRNA^®”) therapeutic platform. Our sd-rxRNA compounds do not require a delivery vehicle to penetrate the cell and are designed to “silence,” or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. We believe that this provides the Company with a distinct advantage in adoptive cell transfer (“ACT”) therapy, the Company’s initial focus and approach to immuno-oncology.

Prior to the Company’s acquisition of MirImmune Inc. (“MirImmune”) in January 2017, the Company’s principal activities consisted of the preclinical and clinical development of our sd-rxRNA compounds and topical immunotherapy agent in the areas of dermatology and ophthalmology. In January 2018, after a thorough review of our business operations, development programs and financial resources, the Company made a strategic decision to focus solely on immuno-oncology to accelerate growth and support a potential return on investment for its stockholders. The Company’s current business strategy focuses on the development of immuno-oncology therapeutics utilizing our proprietary sd-rxRNA technology.

In ACT, immune cells are isolated from specific patients or retrieved from allogeneic immune cell banks, which are banks of cells donated from healthy volunteers. The immune cells are then expanded and modified before being returned and used to treat the same patient. We believe our sd-rxRNA compounds are ideally suited to be used in combination with ACT, in order to make these immune cells more effective. Our approach involves the treatment of the immune cells with our sd-rxRNA compounds during the expansion and modification phase. Because our sd-rxRNA compounds do not require a delivery vehicle to penetrate into the cells, we are able to enhance these cells (for example, by inhibiting the expression of immune checkpoint genes) by merely adding our sd-rxRNA compounds during the expansion process. After enhancing these cells ex-vivo, they are returned to the patient for treatment. In various types of immune cells tested to date, the sd-rxRNA treatment results in potent silencing while maintaining close to 100% transfection efficiency and nearly full cell viability.

We believe that our sd-rxRNA therapeutics are uniquely positioned in the immuno-oncology field for the following reasons:

Our sd-rxRNA compounds do not need facilitated delivery (mechanical or formulation);

Can target multiple genes (i.e. multiple immunosuppression pathways) in a single therapeutic entity;

Demonstrate efficient uptake of sd-rxRNA to immune cells;

Silencing by sd-rxRNA has been shown to have a sustained (long-term) effect in vivo;

Favorable clinical safety profile of sd-rxRNA with local administration; and

Can be readily manufactured under current good manufacturing practices.

We currently have a pipeline of discovery and preclinical programs in three focus areas in which we are aligning our internal research and development efforts with extramural collaborations.

Checkpoint Inhibition in T-Cells

This is our key focus area and our most advanced immuno-oncology program. We have developed sd-rxRNA targeting PD-1, TIGIT and other undisclosed checkpoints in ACT for the treatment of solid tumors. RXI-762 and RXI-804, sd-rxRNA compounds that are designed to suppress the expression of immune checkpoint proteins PD-1 and TIGIT, respectively, which, when used in ACT, are expected to result in an improved efficacy to the targeted tumors.

Our collaboration with the Center for Cancer Immune Therapy at Herlev Hospital, or CCIT, a leading European cancer center, is evaluating the potential of our sd-rxRNA technology platform to enhance the function of tumor-infiltrating lymphocytes (“TILs”) for use in the treatment for a number of cancer types, including melanoma and ovarian cancer. To date, CCIT has evaluated sd-rxRNA compounds targeting immune checkpoints in preclinical screening models of matched TIL/tumor cell pairs from melanoma and cancer patients. Results have shown a marked PD-1 reduction on the surface of TILs in a pilot rapid expansion protocol.

Through our collaboration with Medigene AG, a German biotechnology company developing highly innovative, complementary treatment platforms to target various types and stages of cancer, we are exploring the potential synergies of our sd-rxRNA technology in combination with Medigene’s recombinant TCRs to develop modified T-cells with enhanced efficacy and/or safety with the ultimate goal to further improve Medigene’s T-cell therapies for the treatment of cancer patients. In recent studies, Medigene has observed the reduction of PD-1 surface levels in T-cells transduced with TCRs and treated with our sd-rxRNA compound, RXI-762.

We expect to enter clinical development with RXI-762 as part of an ACT therapy for solid tumors by the end of 2019.

Targets Outside of Checkpoint Inhibition in T-Cells and Other Immune Cell Types

This focus area uses our sd-rxRNA in T-cells and other immune cell types, such as natural killer (“NK”) cells and dendritic cells, for targets other than immune checkpoints in order to weaponize and improve cell persistence and cell viability in the immunosuppressive tumor micro-environment. We believe this shows the broad applicability of our platform technology, and that our potential impact in immuno-oncology is not limited to checkpoints and TILs.

We have shown that sd-rxRNAs are rapidly and efficiently taken up by immune effector cells without the use of transfection reagents. Using sd-rxRNA compounds against checkpoint inhibitors, we can suppress their expression levels up to 95% in immune cells, including T-cells and NK cells. Furthermore, we have demonstrated potent silencing activity as well as a phenotypic effect (enhanced degranulation activity) of NK cells treated with sd-rxRNA compounds targeting checkpoints. By treating NK cells ex-vivo, prior to ACT with sd-rxRNA reducing the expression of proteins such as Cbl-b and TIGIT, the anti-tumor response of these cells can be improved. Ongoing work expands these findings to include compounds for more specific NK targets, including NK specific inhibitory receptors, which could be used alone or in combination.

Tumor and/or Tumor Micro-Environment Targets

Our third focus area includes the use of our sd-rxRNA directly towards tumor and/or tumor micro-environment (“TME”) targets. Impacting the tumor cells and/or tumor micro-environment through a direct use of sd-rxRNA, such as via intra-tumoral injection, could potentially become an important form of adjuvant therapy. We believe that this will also show that our contributions with our sd-rxRNA compounds in immuno-oncology are not limited to use with another company’s cell platform. Additionally, the Company has shown that its sd-rxRNA compounds are safe and well-tolerated via intradermal injections and injections in the eye through its completed clinical trials with RXI-109 in dermatology and ophthalmology.

Our collaborative research agreement with Gustave Roussy, a leading comprehensive cancer center in France, concentrates on determining the feasibility of our sd-rxRNA platform to target TME via intratumoral injection. The goal of our recent study with Gustave Roussy was to identify sd-rxRNA compounds to their target of interest and demonstrate efficacy (silencing and phenotypic effect) of sd-rxRNA compounds in a mouse model. Results from this study showed an 80—85% reduction of the target gene in a mouse model of melanoma via intra-tumoral injection.

We continue to advance our sd-rxRNA technology platform towards clinical development in immuno-oncology, both independently and with our strategic collaborations. We plan to focus our internal resources on therapeutic areas where research and development is appropriate for the size and financial resources of the Company and to seek partners in therapeutic areas with the requisite expertise and resources to advance our product and research candidates through clinical development. We believe that this approach to our strategy will allow us to build upon these current collaborations to add additional partnerships to our immuno-oncology pipeline, support the Company with a shorter path to the clinic by allowing us to utilize and build upon already established protocols of our partners and provide us with the opportunity to expand our immuno-oncology programs and pipeline in multiple areas.

While the Company announced in January 2018 that its current business strategy is to focus solely on its immuno-oncology pipeline development, this year the Company also completed and reported on its clinical trials in dermatology and ophthalmology with RXI-109, our first sd-rxRNA clinical candidate, and Samcyprone^®. The results of the Company’s clinical trials with RXI-109 and Samcyprone are as follows:

In December 2017, the Company announced positive results with RXI-109 in a Phase 2 open-label, multi-center, prospective, within-subject controlled study evaluating the effectiveness and safety of RXI-109 on the outcome of scar revision surgery for hypertrophic scars in healthy adults. The primary effectiveness objective was met as shown by a statistically significant improved visual appearance of revised scars after scar revision surgery and treatment with RXI-109 versus control, as assessed by the investigator. The full study results showed that the product was safe and well tolerated for all dosage groups. Exploratory endpoint analysis furthermore showed that the cosmetic outcomes of RXI-109 treated scars were highly preferred over the untreated revised scars, by both investigators and patients.

In May 2018, the Company announced results from our Phase 2 clinical trial with Samcyprone in cutaneous warts. The primary effectiveness objectives were met as shown by high levels of immunotherapeutic response and therapeutic response. The immunotherapeutic response rate – a prerequisite for therapeutic response – was 97.7% across all 88 subjects enrolled in the study. From a therapeutic response viewpoint, with once weekly dosing for up to 10 weeks, more than 70% of all warts showed a positive wart response rate, i.e. reduction of wart size of more than 50%. Complete wart clearance throughout the study was 54% for all warts, and up to 71.4% for certain wart types (non-plantar warts). The study results show furthermore that Samcyprone was safe and well tolerated.

In August 2018, the Company announced positive results from our Phase 1/2 clinical trial to evaluate the safety and clinical activity of RXI-109 in reducing the progression of retinal scarring. The trial was a multi-dose, dose escalation study conducted in subjects with wet age-related macular degeneration with evidence of subretinal fibrosis. Each subject in the study received four doses of RXI-109 by intraocular injection at one-month intervals for a total dosing period of three months. The primary objective was met as shown by the absence of dose-limiting and serious toxicities, and only mild to moderate procedure related adverse events. None of the adverse events were drug related. In addition, comprehensive ocular examinations showed no indications of inflammation nor any other tolerability issues related to the treatment. The secondary objective of the study was also met with improved or stable disease in the study eyes of several subjects.

On January 3, 2018, the Board of Directors of the Company approved a 1-for-10 reverse stock split of the Company’s outstanding common stock, which was effected on January 8, 2018. All share and per share amounts have been retroactively adjusted for all periods presented to give effect to the reverse stock split, including reclassifying an amount equal to the reduction in par value to additional paid-in capital in the financial statements.

On April 11, 2018, the Company closed a registered direct offering of 1,510,604 shares of the Company’s common stock at a purchase price of $3.15 per share (the “April 2018 Offering”) pursuant to the Securities Purchase Agreement dated as of April 9, 2018, by and among the Company and each purchaser identified on the signature pages thereto. In a concurrent private placement, the Company sold warrants (the “Warrants”) to purchase a total of 1,132,953 shares of common stock at a purchase price of $0.125 per underlying warrant share and with an exercise price of $3.15 per share (the “Private Placement”). In connection with the Offering and Private Placement, the Company issued warrants to purchase a total of 75,530 shares of common stock with an exercise price of $4.0546 per share to the placement agent, H.C. Wainwright & Co., LLC (the “Placement Agent Warrants”). Assuming the Warrants and Placement Agent Warrants are not exercised, net proceeds to the Company from the Offering and Private Placement were $4,210,000 after deducting placement agent fees and offering expenses paid by the Company.

On October 3, 2018, the Company closed an underwritten public offering (the “October 2018 Offering”) of (i) 3,725,714 units (the “Units”), at a public offering price of $0.70 per Unit, with each Unit consisting of one share of common stock and one warrant (the “October 2018 Warrants”) to purchase one share of common stock and (ii) 17,702,858 pre-funded units (the “Pre-Funded Units”), at a public offering price of $0.69 per Pre-Funded Unit, with each Pre-Funded Unit consisting of one pre-funded warrant (the “Pre-Funded Warrants”) to purchase one share of common stock and one October 2018 Warrant. The October 2018 Warrants included in the Units and Pre-Funded Units are immediately exercisable at a price of $0.70 per share and expire seven years from the date of issuance. The Pre-Funded Warrants included in the Pre-Funded Units are immediately exercisable at a price per share of $0.01 and do not expire. Assuming the October 2018 Warrants are not exercised, net proceeds from the October 2018 Offering were approximately $13,300,000 after deducting underwriting discounts and commissions and offering expenses paid by the Company. Additionally, pursuant to the October 2018 Offering, the Company issued warrants to purchase up to 1,607,143 shares of common stock at an exercise price of $0.875 per share to the underwriter, H.C. Wainwright & Co., LLC.

Critical Accounting Policies and Estimates

There have been no significant changes to our critical accounting policies since the beginning of this fiscal year. Our critical accounting policies are described in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the year ended December 31, 2017, which we filed with the SEC on March 26, 2018.

Results of Operations

The following data summarizes the results of our operations for the periods indicated, in thousands:

	Three Months Ended September 30,								Nine Months Ended September 30,
Description	2018			2017			Dollar Change		2018			2017			Dollar Change
Revenues	$	57		$	–		$	57	$	138		$	–		$	138
Operating expenses		(1,549	)		(2,476	)		927		(5,768	)		(12,071	)		6,303
Operating loss		(1,492	)		(2,476	)		984		(5,630	)		(12,071	)		6,441
Income tax benefit		–			–			–		–			1,621			(1,621	)
Net loss		(1,493	)		(2,476	)		983		(5,633	)		(10,450	)		4,817

Comparison of the Three and Nine Months Ended September 30, 2018 and 2017

Revenues

The following table summarizes our total revenues, for the periods indicated, in thousands:

Three Months Ended September 30,

Nine Months Ended September 30,

Description

2018

2017

Dollar

Change

2018

2017

Dollar Change

Revenues

–

138

–

138

Revenues for the three and nine months ended September 30, 2018 related to the work performed by the Company as a sub-awardee under the government grant issued to our collaborator BioAxone Biosciences, Inc. from the National Institute of Neurological Disorders and Stroke. The grant provides funding for the development of a novel sd-rxRNA compound, BA-434, that targets PTEN for the treatment of spinal cord injury. There were no revenues for the three and nine months ended September 30, 2017.

Operating Expenses

The following table summarizes our total operating expenses, for the periods indicated, in thousands:

	Three Months Ended September 30,							Nine Months Ended September 30,
Description	2018		2017		Dollar Change			2018		2017		Dollar Change
Research and development	$	838	$	1,490	$	(652	)	$	3,382	$	4,166	$	(784	)
Acquired in-process research and development		–		–		–			–		4,696		(4,696	)
General and administrative		711		986		(275	)		2,386		3,209		(823	)
Total operating expenses	$	1,549	$	2,476	$	(927	)	$	5,768	$	12,071	$	(6,303	)

Research and Development Expenses

Research and development expenses relate to salaries, employee benefits, facility-related expenses, supplies, stock-based compensation related to employees and non-employees involved in the Company’s research and development, external services, other operating costs and overhead related to our research and development departments, costs to acquire technology licenses and expenses associated with our preclinical activities and clinical trials.

Research and development expenses for the three months ended September 30, 2018 decreased 44% compared with the three months ended September 30, 2017, primarily due to a decrease in clinical-trial related expenses as subject participation is complete for all of the Company’s clinical trials in dermatology and ophthalmology and a decrease in payroll-related expenses due to a reduction in headcount as compared with the prior year period.

Research and development expenses for the nine months ended September 30, 2018 decreased 19% compared with the nine months ended September 30, 2017, primarily due to a decrease in expenses related to the Company’s dermatology and ophthalmology programs, including clinical trial and manufacturing fees, as these projects ramp down with the Company’s sole focus on immuno-oncology and a decrease in payroll-related expenses due to a reduction in headcount as compared with the prior year period.

Acquired In-process Research and Development Expense

In January 2017, the Company acquired all of the issued and outstanding capital stock of MirImmune, a privately-held biotechnology company that was engaged in the development of cancer immunotherapies, in exchange for securities of the Company. The Company determined that the acquired assets did not constitute a business and that the transaction would be accounted for as an asset acquisition. As the assets and development programs acquired from MirImmune were at an early stage of development and determining the future economic benefit of the acquired assets at the date of acquisition was highly uncertain, the fair value of the assets was fully expensed as in-process research and development expense.

There was no acquired in-process research and development expense during the three months ended September 30, 2018 or 2017 or for the nine months ended September 30, 2018. During the nine months ended September 30, 2017, the Company recorded acquired in-process research and development expense related to the fair value of consideration given, which included transaction costs, liabilities assumed and cancellation of notes receivable, and the deferred tax impact of the acquisition of MirImmune.

General and Administrative Expenses

General and administrative expenses relate to salaries, employee benefits, facility-related expenses, stock-based compensation expense related to employees dedicated to general and administrative activities. Other general and administrative expenses include professional fees for legal, audit, tax and consulting services, as well as other general corporate expenses.

General and administrative expenses for the three months ended September 30, 2018 decreased 28% compared with the three months ended September 30, 2017, primarily due to decreases in payroll-related expenses, including those related to a reduction in headcount.

General and administrative expenses for the nine months ended September 30, 2018 decreased 26% compared with the nine months ended September 30, 2017, primarily due to decreases in payroll-related expenses, including those related to a reduction in headcount, as well as a decrease in professional fees for legal-related services.

Income Tax

The following table summarizes the Company’s income tax for the periods indicated, in thousands:

Three Months Ended September 30,

Nine Months Ended September 30,

Description

2018

2017

Dollar

Change

2018

2017

Dollar Change

Income tax benefit

–

1,621

(1,621

)

There was no income tax during the three months ended September 30, 2018 or 2017 or for the nine months ended September 30, 2018. For the nine months ended September 30, 2017, we recognized an income tax benefit for the tax-related impact of the Company’s acquisition of MirImmune in January 2017.

Liquidity and Capital Resources

On August 8, 2017, the Company entered into a purchase agreement (the “LPC Purchase Agreement”) and a registration rights agreement with Lincoln Park Capital Fund, LLC (“LPC”), pursuant to which the Company has the right to sell to LPC up to $15,000,000 in shares of the Company’s common stock, subject to certain limitations and conditions set forth therein, over the 30-month term of the LPC Purchase Agreement. During the nine months ended September 30, 2018, the Company sold 435,000 shares of common stock to LPC for net proceeds of approximately $1,312,000. In total, the Company has sold 495,000 shares of common stock to LPC for net proceeds of approximately $1,602,000.

On April 11, 2018, the Company closed on the April 2018 Offering and Private Placement of its common stock and the Warrants. Assuming the Warrants and Placement Agent Warrants are not exercised, net proceeds to the Company from the Offering and Private Placement were $4,210,000 after deducting placement agent fees and offering expenses paid by the Company.

On October 3, 2018, the Company closed on the October 2018 Offering of its Units and Pre-Funded Units. Assuming the October 2018 Warrants included in the Units and Pre-Funded Units are not exercised, net proceeds from the October 2018 Offering were approximately $13,300,000 after deducting underwriting discounts and commissions and offering expenses paid by the Company.

We had cash and cash equivalents of $3,240,000 as of September 30, 2018, compared with $3,581,000 as of December 31, 2017. We have reported recurring losses from operations since inception and expect that we will continue to have negative cash flows from our operations for the foreseeable future. Historically, the Company’s primary source of funding has been the sale of its securities. In the future, we will be dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, or strategic opportunities, in order to maintain our operations. There is no guarantee that debt, additional equity or other funding will be available to us on acceptable terms, or at all. If we fail to obtain additional funding when needed, we would be forced to scale back or terminate our operations or to seek to merge with or to be acquired by another company. We believe that our existing cash, the net proceeds from the April 2018 Offering and the net proceeds from the October 2018 Offering should be sufficient to fund our operations for at least the next twelve months.

The following table summarizes our cash flows for the periods indicated, in thousands:

	Nine Months Ended September 30,
	2018			2017
Net cash used in operating activities	$	(5,774	)	$	(7,313	)
Net cash used in investing activities		–			(103	)
Net cash provided by (used in) financing activities		5,433			(74	)
Net decrease in cash, cash equivalents and restricted cash	$	(341	)	$	(7,490	)

Net Cash Flow from Operating Activities

Net cash used in operating activities was $5,774,000 for the nine months ended September 30, 2018 compared with $7,313,000 for the nine months ended September 30, 2017. The decrease in cash used in operating activities of $1,539,000 was primarily attributable to a decrease in net loss offset by adjustments for non-cash expenses, primarily acquired in-process research and development expense and deferred tax related to the Company’s acquisition of MirImmune in the prior year.

Net Cash Flow from Investing Activities

There were no net cash flows related to investing activities for the nine months ended September 30, 2018. Net cash used in investing activities was $103,000 for the nine months ended September 30, 2017. The decrease in net cash flow from investing activities was primarily related to the purchase of laboratory equipment in the prior year.

Net Cash Flow from Financing Activities

Net cash provided by financing activities was $5,433,000 for the nine months ended September 30, 2018 and was due to proceeds received by the Company from the April 2018 Offering, Private Placement and the issuance of common stock to LPC. Net cash used in financing activities for the nine months ended September 30, 2017 was $74,000 and was due to offering costs in relation to the LPC Purchase Agreement.

Off-Balance Sheet Arrangements

In connection with certain license agreements, we are required to indemnify the licensor for certain damages arising in connection with the intellectual property rights licensed under the agreement. In addition, we are a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate us to indemnify the other parties to such agreements upon the occurrence of certain events. These indemnification obligations are considered off-balance sheet arrangements in accordance with Accounting Standards Codification Topic 460, “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others.” To date, we have not encountered material costs as a result of such obligations and have not accrued any liabilities related to such obligations in our financial statements. See Note 7 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the Securities and Exchange Commission on March 26, 2018, for further discussion of these indemnification agreements.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and acting Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission (the “SEC”) rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and acting Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Based on the evaluation of our disclosure controls and procedures as of the end of the period covered by this report, management has concluded that our disclosure controls and procedures were not effective as of such date due to the material weakness in internal control over financial reporting that was disclosed in Part II, Item 9A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

Remediation Plan

As previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, management has implemented a remediation plan to address the control deficiency that led to the material weakness in internal control over financial reporting related to our controls over accounting for income taxes. The remediation plan includes (i) the implementation of increased involvement on a quarterly basis with our third-party tax accountants dedicated to determining the appropriate accounting for material and complex tax transactions in a timely manner, (ii) the review of our tax accounting processes to identify and implement enhanced tax accounting processes and related internal control procedures and (iii) establishing additional training and education programs for financial personnel responsible for income tax accounting.

Management believes the implementation of the measures described above will remediate the control deficiencies identified and will strengthen our internal control over financial reporting. The material weakness cannot be considered remediated until the control has operated for a sufficient period of time and until management has concluded, through testing, that the control is operating effectively. We expect these remedial actions to be effectively implemented in order to successfully remediate the material weakness by the end of 2018.

Changes in Internal Control Over Financial Reporting

Other than the changes noted in the Remediation Plan section above, which were implemented during the quarterly period ended March 31, 2018, there has not been any change in our internal control over financial reporting that occurred during the nine months ended September 30, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

From time to time, the Company is party to legal proceedings. There are none deemed to be material at this time.

ITEM 1A.

RISK FACTORS

Please carefully consider the information set forth in this Quarterly Report on Form 10-Q and the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission on March 26, 2018. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including these risks.

We may not be able to regain compliance with the continued listing requirements of The Nasdaq Capital Market.

On November 12, 2018, we received written notice (the “Notification Letter”) from the Nasdaq Stock Market (“Nasdaq”) notifying us that we are not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of our common stock for the 30 consecutive business days prior to the date of the Notification Letter, we no longer meet the minimum bid price requirement.

The Notification Letter does not impact our listing on The Nasdaq Capital Market at this time. The Notification Letter states that we have 180 calendar days, or until May 13, 2019, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of our common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to May 13, 2019. In the event that we do not regain compliance by May 13, 2019, we may be eligible for additional time to reach compliance with the minimum bid price requirement. However, if we fail to regain compliance with the minimum bid price listing requirement or fail to maintain compliance with all other applicable continued listing requirements and Nasdaq determines to delist our common stock, the delisting could adversely impact us by, among other things, reducing the liquidity and market price of our common stock; reducing the number of investors willing to hold or acquire our common stock; limiting our ability to issue additional securities in the future; and limiting our ability to fund our operations.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS

EXHIBIT INDEX

		Incorporated by Reference Herein
Exhibit Number	Description	Form	Date

31.1	Sarbanes-Oxley Act Section 302 Certification of Chief Executive Officer and Chief Financial Officer.*

32.1	Sarbanes-Oxley Act Section 906 Certification of Chief Executive Officer and Chief Financial Officer.*

101	The following financial information from the Quarterly Report on Form 10-Q of RXi Pharmaceuticals Corporation for the quarter ended September 30, 2018, formatted in XBRL (eXtensible Business Reporting Language): (1) Condensed Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017; (2) Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2018 and 2017; (3) Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2018 and 2017; and (4) Notes to Condensed Consolidated Financial Statements (Unaudited).*

Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	RXi Pharmaceuticals Corporation

	By:		/s/ Geert Cauwenbergh
			Geert Cauwenbergh, Dr. Med. Sc.
			President, Chief Executive Officer and acting Chief Financial Officer

			Date: November 14, 2018

EX-31.1 2 rxi_10q-ex3101.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Geert Cauwenbergh, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of RXi Pharmaceuticals Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Dated: November 14, 2018

/s/ Geert Cauwenbergh

Geert Cauwenbergh, Dr. Med. Sc.

President, Chief Executive Officer and acting Chief Financial Officer

(as Principal Executive and Financial Officer)

EX-32.1 3 rxi_10q-ex3201.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of RXi Pharmaceuticals Corporation (the “Company”) for the period ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the Company’s financial condition and result of operations.

/s/ Geert Cauwenbergh

Geert Cauwenbergh, Dr. Med. Sc.

President, Chief Executive Officer and acting Chief Financial Officer

(as Principal Executive and Financial Officer)

November 14, 2018

EX-101.INS 4 rxii-20180930.xml XBRL INSTANCE FILE 0001533040 2017-09-30 0001533040 2018-09-30 0001533040 2016-12-31 0001533040 2017-12-31 0001533040 2018-01-01 2018-01-03 0001533040 2017-01-01 2017-09-30 0001533040 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0001533040 2018-01-01 2018-09-30 0001533040 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001533040 2018-11-09 0001533040 2018-07-01 2018-09-30 0001533040 2017-07-01 2017-09-30 0001533040 rxii:LpcPurchaseAgrMember 2018-07-01 2018-09-30 0001533040 rxii:LpcPurchaseAgrMember 2018-01-01 2018-09-30 0001533040 rxii:AprilOfferingMember us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001533040 rxii:OfferingAndPrivatePlacementMember 2018-01-01 2018-09-30 0001533040 rxii:AprilOfferingMember us-gaap:CommonStockMember 2018-04-11 0001533040 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2018-04-11 0001533040 rxii:OfferingAndPrivatePlacementMember rxii:WainwrightMember 2018-04-11 0001533040 us-gaap:WarrantMember rxii:WarrantPrice1Member 2018-01-01 2018-09-30 0001533040 us-gaap:WarrantMember rxii:WarrantPrice2Member 2018-01-01 2018-09-30 0001533040 us-gaap:WarrantMember rxii:WarrantPrice3Member 2018-01-01 2018-09-30 0001533040 us-gaap:WarrantMember rxii:WarrantPrice4Member 2018-01-01 2018-09-30 0001533040 us-gaap:WarrantMember rxii:WarrantPrice1Member 2018-09-30 0001533040 us-gaap:WarrantMember rxii:WarrantPrice2Member 2018-09-30 0001533040 us-gaap:WarrantMember rxii:WarrantPrice3Member 2018-09-30 0001533040 us-gaap:WarrantMember rxii:WarrantPrice4Member 2018-09-30 0001533040 us-gaap:WarrantMember 2018-09-30 0001533040 us-gaap:StockOptionMember 2018-01-01 2018-09-30 0001533040 us-gaap:StockOptionMember 2017-01-01 2017-09-30 0001533040 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001533040 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001533040 us-gaap:StockOptionMember 2018-01-01 2018-09-30 0001533040 us-gaap:StockOptionMember 2017-12-31 0001533040 us-gaap:StockOptionMember 2018-09-30 0001533040 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001533040 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-09-30 0001533040 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0001533040 us-gaap:GeneralAndAdministrativeExpenseMember 2017-07-01 2017-09-30 0001533040 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-09-30 0001533040 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0001533040 us-gaap:SeriesBPreferredStockMember 2018-01-01 2018-09-30 0001533040 us-gaap:SeriesCPreferredStockMember 2018-01-01 2018-09-30 0001533040 us-gaap:SeriesCPreferredStockMember 2017-01-01 2017-09-30 0001533040 srt:MinimumMember 2017-07-01 2017-09-30 0001533040 srt:MinimumMember 2017-01-01 2017-09-30 0001533040 srt:MaximumMember 2017-07-01 2017-09-30 0001533040 srt:MaximumMember 2017-01-01 2017-09-30 0001533040 srt:MinimumMember 2018-01-01 2018-09-30 0001533040 srt:MaximumMember 2018-01-01 2018-09-30 0001533040 us-gaap:SeriesBPreferredStockMember 2017-01-01 2017-09-30 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-09-30 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2018-09-30 0001533040 us-gaap:StockOptionMember 2017-07-01 2017-09-30 0001533040 us-gaap:StockOptionMember 2017-01-01 2017-09-30 0001533040 us-gaap:StockOptionMember 2018-01-01 2018-09-30 0001533040 us-gaap:StockOptionMember 2018-07-01 2018-09-30 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2018-09-30 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0001533040 rxii:CauwenberghMember us-gaap:RestrictedStockMember 2018-07-01 2018-09-30 0001533040 rxii:CauwenberghMember us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0001533040 us-gaap:SubsequentEventMember rxii:October2018OfferingMember rxii:UnitsMember 2018-01-01 2018-10-03 0001533040 us-gaap:SubsequentEventMember rxii:October2018OfferingMember rxii:UnitsMember 2018-10-03 0001533040 us-gaap:SubsequentEventMember rxii:October2018OfferingMember rxii:WainwrightMember 2018-01-01 2018-10-03 0001533040 us-gaap:SubsequentEventMember rxii:October2018OfferingMember rxii:PreFundedUnitsMember 2018-01-01 2018-10-03 0001533040 us-gaap:SubsequentEventMember rxii:October2018OfferingMember rxii:PreFundedUnitsMember 2018-10-03 0001533040 us-gaap:SubsequentEventMember rxii:October2018OfferingMember rxii:WainwrightMember 2018-10-03 0001533040 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0001533040 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2017-07-01 2017-09-30 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-09-30 0001533040 us-gaap:SubsequentEventMember rxii:October2018OfferingMember rxii:October2018WarrantsMember 2018-10-03 0001533040 us-gaap:SubsequentEventMember rxii:October2018OfferingMember rxii:PreFundedUnitsMember rxii:PreFundedWarrantsMember 2018-10-03 0001533040 us-gaap:SubsequentEventMember rxii:PreFundedWarrantsMember us-gaap:CommonStockMember 2018-01-01 2018-11-05 0001533040 us-gaap:SubsequentEventMember rxii:October2018OfferingMember 2018-01-01 2018-10-03 0001533040 rxii:CauwenberghMember us-gaap:RestrictedStockMember 2017-07-01 2017-09-30 0001533040 rxii:CauwenberghMember us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0001533040 us-gaap:SubsequentEventMember rxii:October2018OfferingMember rxii:PreFundedUnitsMember rxii:PreFundedWarrantsMember 2018-01-01 2018-10-03 xbrli:shares iso4217:USD xbrli:shares iso4217:USD xbrli:pure 18164356

3.15

4.0546

52.00

9.00

3.15

4.0546

0.70

0.875

0.70

0.01

1132953

75530

5466000

3290000

12956000

3631000

1568000

1754000

3622000

3832000

85934000

80384000

491000

511000

3809000

4098000

3240000

3581000

100000000

4449909

2429993

130007

1277793

1132953

75530

2616283

0.0001

4449909

2429993

3809000

4098000

2059000

2265000

0.0001

10000000

332000

201000

187000

248000

-84184000

-78551000

38939

50180

157514

192.30

62.35

1750000

1833000

18000

-74000

5433000

4210000

13300000

15000

435000

1510604

3725714

.001

Company approved a 1-for-10 reverse stock split of the Company’s outstanding common stock, which was effected on January 8, 2018.

1461100

2998634

157514

53100

2616283

1408000

151250

73587

100000

-7490000

-341000

48000

61000

-4.71

-1.54

-0.34

-1.05

3209000

2386000

711000

986000

-12071000

-5633000

-1493000

-2476000

276000

-186000

-1621000

-417000

-20000

121000

113000

12071000

5768000

1549000

2476000

-10450000

-5633000

-1493000

-2476000

5000

-12071000

-5630000

-1492000

-2476000

-3000

-1000

150000

203000

4166000

3382000

838000

1490000

276000

80000

117000

29000

39000

43000

9000

7000

30000

36000

196000

88000

43000

276000

95000

17000

22000

4.90

1.75

1.72

2216775

3662924

4371259

2351144

false --12-31 Q3 2018 10-Q 2018-09-30 RXi Pharmaceuticals Corp 0001533040 Non-accelerated Filer

21000

1312000

138000

57000

916

29.50

1.83

108250

RXII 2020-06-02 2021-12-21 2023-05-31 2023-04-09

50000

-7313000

-5774000

-103000

-74000

5433000

.0293

.0173

.0270

.0194

.0249

.0293

.0235

1.6145

.8299

.9128

.8387

1.2301

1.6145

.9199

.8465

1.5955

1.6145

.8793

0.00

4696000

-1621000

816000

3525000

2824000

3.15

0.125

0.70

0.69

P6Y3M

P5Y2M12D

P10Y

P5Y6M

P10Y

true false

Stock-based Compensation   The Company follows the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, “Compensation — Stock Compensation” (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, officers, non-employee directors, and non-employees, including stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; padding-bottom: 1pt">Exercise price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Number of Shares Underlying Warrants</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Expiration</td><td style="font-weight: bold; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 1%; text-align: left">$</td><td style="width: 60%; text-align: left">52.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">130,007</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">June 2, 2020</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: left">9.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,277,793</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">December 21, 2021</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">$</td><td style="text-align: left">3.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,132,953</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">May 31, 2023</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: left">4.0546</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">75,530</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">April 9, 2023</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: left">Total warrants outstanding</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,616,283</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

151250

1.79

3725714 1607143 One share of common stock and one warrant

244.14

1. Nature of Operations   RXi Pharmaceuticals Corporation (“RXi,” “we,” “our” or the “Company”) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (“sd-rxRNA®”) therapeutic platform. The Company’s sd-rxRNA compounds do not require a delivery vehicle to penetrate the cell and are designed to “silence,” or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. We believe that this provides RXi with a distinct advantage in adoptive cell transfer therapy, the Company’s initial focus and approach to immuno-oncology.   Prior to the Company’s acquisition of MirImmune Inc. in January 2017, our principal activities consisted of the preclinical and clinical development of the Company’s sd-rxRNA compounds and topical immunotherapy agent in the areas of dermatology and ophthalmology. In January 2018, after a thorough review of its business operations, development programs and financial resources, the Company made a strategic decision to focus solely on immuno-oncology to accelerate growth and support a potential return on investment for its stockholders. The Company’s current business strategy focuses on the development of immuno-oncology therapeutics utilizing our proprietary sd-rxRNA technology.   The Company intends to seek a partner and/or out-licensee for each of its dermatology and ophthalmology franchises, including RXI-109 and Samcyprone®, to continue their development. The goal of any such transaction would be to allow the Company to monetize these preclinical and clinical assets to further fund ongoing and future development work in our immuno-oncology programs and extend our financial runway.   On January 3, 2018, the Board of Directors of the Company approved a 1-for-10 reverse stock split of the Company’s outstanding common stock, which was effected on January 8, 2018. All share and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split, including reclassifying an amount equal to the reduction in par value to additional paid-in capital.

2. Significant Accounting Policies   Basis of Presentation   The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Certain information and footnote disclosures included in the Company’s annual financial statements have been condensed or omitted. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included. Interim results are not necessarily indicative of results for a full year.   Principles of Consolidation   The consolidated financial statements include the accounts of RXi Pharmaceuticals Corporation and its wholly-owned subsidiary, MirImmune, LLC. All material intercompany accounts have been eliminated in consolidation.   Uses of Estimates in Preparation of Financial Statements   The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from these estimates.   Cash Equivalents and Restricted Cash   The Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in certificates of deposit.   Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards.   Fair Value of Financial Instruments   The carrying amounts reported in the balance sheet for cash equivalents, restricted cash, accounts payable and accrued expenses approximate their fair values due to their short-term nature.   Research and Development Expenses   Research and development costs relate to salaries, employee benefits, facility-related expenses, supplies, stock-based compensation related to employees and non-employees involved in the Company’s research and development, external services, other operating costs and overhead related to its research and development departments, costs to acquire technology licenses and expenses associated with preclinical activities and its clinical trials. Research and development expenses are charged to expense as incurred. Payments made by the Company in advance for research and development services not yet provided and/or for materials not yet received are recorded as prepaid expenses and expensed when the service has been performed or when the goods have been received. Accrued liabilities are recorded related to those expenses for which vendors have not yet billed the Company with respect to services provided and/or materials that it has received.    Preclinical and clinical trial expenses relate to estimates of costs incurred and fees connected with clinical trial sites, third-party clinical research organizations and other preclinical and clinical related activities and include such items as subject-related fees, laboratory work, investigator fees and analysis costs. Costs associated with these expenses are generally payable on the passage of time or when certain milestones are achieved. Expense is recorded during the period incurred or in the period in which a milestone is achieved. In order to ensure that the Company has adequately provided for preclinical and clinical expenses during the proper period, the Company maintains an accrual to cover these expenses. These accruals are assessed on a quarterly basis and are based on such assumptions as expected total cost, the length of the study, timing of certain milestones and other information available to us. Actual results may differ from these estimates and could have a material impact on the Company’s reported results. The Company’s historical accrual estimates have not been materially different from its actual costs.   Stock-based Compensation   The Company follows the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, “Compensation — Stock Compensation” (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, officers, non-employee directors, and non-employees, including stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period.   Income Taxes   The Company recognizes assets or liabilities for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with the FASB ASC Topic 740, “Accounting for Income Taxes.” On December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act tax reform legislation. This legislation makes significant changes in U.S. tax law including a reduction in the corporate tax rates, changes to net operating loss carryforwards and carrybacks, and a repeal of the corporate alternative minimum tax. The Company is continuing to assess the impact of the Tax Cuts and Jobs Act and does not expect the provisions to have a material impact on the Company’s consolidated financial statements.   Comprehensive Loss   The Company’s comprehensive loss is equal to its net loss for all periods presented.   Net Loss per Share   The Company accounts for and discloses net loss per share in accordance with the FASB ASC Topic 260, “Earnings per Share.” Basic and diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares.

4. Stockholders’ Equity   Lincoln Park Capital Fund, LLC – On August 8, 2017, the Company entered into a purchase agreement (the “LPC Purchase Agreement”) and a registration rights agreement with LPC, pursuant to which the Company has the right to sell to LPC shares of the Company’s common stock, subject to certain limitations and conditions set forth in the LPC Purchase Agreement.   During the three months ended September 30, 2018, the Company sold 15,000 shares of common stock to LPC for net proceeds of approximately $21,000. During the nine months ended September 30, 2018, the Company sold 435,000 shares of common stock to LPC for net proceeds of approximately $1,312,000.   April 2018 Registered Direct Offering and Private Placement – On April 11, 2018, the Company closed a registered direct offering of 1,510,604 shares of the Company’s common stock at a purchase price of $3.15 per share (the “April 2018 Offering”) pursuant to the Securities Purchase Agreement dated as of April 9, 2018, by and among the Company and each purchaser identified on the signature pages thereto. In a concurrent private placement, the Company sold warrants (the “Warrants”) to purchase a total of 1,132,953 shares of common stock at a purchase price of $0.125 per underlying warrant share and with an exercise price of $3.15 per share (the “Private Placement”). In connection with the April 2018 Offering and Private Placement, the Company issued warrants to purchase a total of 75,530 shares of common stock with an exercise price of $4.0546 per share to the placement agent, H.C. Wainwright & Co., LLC (the “Placement Agent Warrants”). Assuming the Warrants and Placement Agent Warrants are not exercised, net proceeds to the Company from the April 2018 Offering and Private Placement were $4,210,000 after deducting placement agent fees and offering expenses paid by the Company.   The Company assessed the Warrants and Placement Agent Warrants under the FASB ASC Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”) and determined that the Warrants and Placement Agent Warrants were outside the scope of ASC 480. The Company next assessed the Warrants and Placement Agent Warrants under the FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). Under the related guidance, a reporting entity shall not consider a contract to be a derivative instrument if the contract is both (1) indexed to the entity’s own stock and (2) classified in stockholders’ equity. The Company determined that the Warrants and Placement Agent Warrants were indexed to the Company’s stock, as the agreements do not contain any exercise contingencies and the settlement amount equals the difference between the fair value of the Company’s common stock price and the strike price. The Company also assessed the classification in stockholders’ equity and determined the Warrants and Placement Agent Warrants met all of the criteria for classification as equity under ASC 815. Based on this analysis, the Company determined that the Warrants and Placement Agent Warrants would be classified in stockholders’ equity.    Warrants — The following table summarizes the Company’s outstanding equity-classified warrants at September 30, 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Exercise price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares Underlying Warrants</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Expiration</td><td style="font-weight: bold; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 1%; text-align: left">$</td><td style="width: 64%; text-align: left">52.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">130,007</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">June 2, 2020</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: left">9.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,277,793</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">December 21, 2021</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">$</td><td style="text-align: left">3.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,132,953</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">May 31, 2023</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: left">4.0546</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">75,530</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">April 9, 2023</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: left">Total warrants outstanding</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,616,283</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5. Net Loss per Share   The following table sets forth the potential common shares excluded from the calculation of net loss per share because their inclusion would be anti-dilutive:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Options to purchase common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">157,514</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">53,100</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unvested, restricted stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73,587</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">151,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,616,283</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,408,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,998,634</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,461,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Income Taxes   The Company recognizes assets or liabilities for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with the FASB ASC Topic 740, “Accounting for Income Taxes.” On December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act tax reform legislation. This legislation makes significant changes in U.S. tax law including a reduction in the corporate tax rates, changes to net operating loss carryforwards and carrybacks, and a repeal of the corporate alternative minimum tax. The Company is continuing to assess the impact of the Tax Cuts and Jobs Act and does not expect the provisions to have a material impact on the Company’s consolidated financial statements.

Net Loss per Share   The Company accounts for and discloses net loss per share in accordance with the FASB ASC Topic 260, “Earnings per Share.” Basic and diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">2.93</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">1.94 – 2.35</td><td style="width: 1%; text-align: left">%</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">2.70 – 2.93</td><td style="width: 1%; text-align: left">%</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">1.73 – 2.49</td><td style="width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161.45</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83.87 – 91.99</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">91.28 – 161.45</td><td style="text-align: left">%</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">82.99 – 123.01</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Weighted average expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161.45</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87.93</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">159.55</td><td style="text-align: left">%</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">84.65</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected lives (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.25 – 10.00</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.50 – 10.00</td><td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">5.20 – 10.00</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td> </tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">9</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">29</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">80</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">36</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">88</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">196</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 11pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">39</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">43</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">117</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">276</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

One pre-funded warrant and one warrant 17702858

P7Y

73587

Convertible into one share of common stock

10534286

105000

3. Recent Accounting Pronouncements   In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. On July 9, 2015, the FASB voted to delay the effective date of the new revenue standard by one year but to permit entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU 2016-08, “Revenue from Contracts with Customers (Topic 606) – Principal Versus Agent Considerations,” which improves the operability and understandability of the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606) – Identifying Performance Obligations and Licensing,” which clarifies two aspects of the guidance on accounting for revenue contracts with customers: identifying performance obligations and the licensing implementation guidance. In May 2016, the FASB issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606) – Narrow Scope Improvements and Practical Expedients,” which addresses collectability assessment, presentation of sales taxes, noncash consideration and completed contracts and contract modifications at transition. The amendments in these ASUs do not change the core principles for those areas. This standard became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is not permitted. The Company adopted this ASU in the first quarter of 2018. Since the Company has no significant revenue, this ASU had no immediate impact on its consolidated financial statements.    In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842),” which requires companies that are lessees to recognize a right-of-use asset and lease liability for most leases that do not meet the definition of a short-term lease. For income statement purposes, leases will continue to be classified as either operating or financing. Classification will be based on criteria that are largely similar to those applied in current lease accounting. This standard will result in extensive qualitative and quantitative disclosure changes. In July 2018, the FASB issued ASU 2018-10, “Codification Improvements to Topic 842, Leases,” which affects narrow aspects of the guidance issued in the amendments in ASU 2016-02, “Leases.” The FASB further issued ASU 2018-11, “Leases (Topic 842): Targeted Improvements”, in July 2018, which provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption consistent with preparers’ requests. This standard will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. The Company is currently evaluating the impact of this ASU on its consolidated financial statements, but expects that the adoption will result in the current operating lease being recorded on the consolidated balance sheet.   In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718) – Improvements to Nonemployee Share-Based Payment Accounting,” which expands the scope of ASC 718 to include share-based payment transactions for acquiring goods and services from non-employees. The amendment specifies that ASC 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. This standard will be effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company early adopted this ASU in the second quarter of 2018. The ASU had no material impact on the Company’s consolidated financial statements.   In August 2018, the Securities and Exchange Commission issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to the Company’s financial reporting will be the inclusion of the annual disclosure requirement of changes in stockholders’ equity in Rule 3-04 of Regulation S-X to interim periods. We will adopt this new rule beginning with our financial reporting for the quarter ended March 31, 2019. Upon adoption, the Company will include the consolidated Statements of Stockholders’ Equity with each quarterly filing on Form 10-Q.

6. Stock-based Compensation   Stock Options   The Company uses the Black-Scholes option-pricing model to determine the fair value of all its option grants. For valuing options granted during the three and nine months ended September 30, 2018 and 2017, the following assumptions were used:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">2.93</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">1.94 – 2.35</td><td style="width: 1%; text-align: left">%</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">2.70 – 2.93</td><td style="width: 1%; text-align: left">%</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">1.73 – 2.49</td><td style="width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161.45</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83.87 – 91.99</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">91.28 – 161.45</td><td style="text-align: left">%</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">82.99 – 123.01</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Weighted average expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161.45</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87.93</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">159.55</td><td style="text-align: left">%</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">84.65</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected lives (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.25 – 10.00</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.50 – 10.00</td><td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">5.20 – 10.00</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td> </tr> </table>    The weighted average fair value of options granted during the three months ended September 30, 2018 and 2017 was $1.72 and $4.90, respectively. The weighted average fair value of options granted during the nine months ended September 30, 2018 and 2017 was $1.75 and $4.90, respectively.   The risk-free interest rate used for each grant is based upon the yield on zero-coupon U.S. Treasury securities with a term similar to the expected life of the related option. The Company’s expected stock price volatility assumption is based upon the Company’s own implied volatility. The expected life assumption for option grants is based upon the simplified method provided for under ASC 718. The dividend yield assumption is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends.   The following table summarizes the activity of the Company’s stock options for the nine months ended September 30, 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted- Average Exercise Price Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 1%; text-align: left"> </td><td style="width: 53%; text-align: left">Balance at December 31, 2017</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">50,180</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">192.30</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">  </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left"> </td><td style="text-align: left">Exercised</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: left">Cancelled</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(916</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">29.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: left">Balance at September 30, 2018</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">157,514</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">62.35</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: left">Exercisable at September 30, 2018</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">38,939</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">244.14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Stock-based compensation expense related to stock options for the three months ended September 30, 2018 and 2017 was $17,000 and $43,000, respectively.   Stock-based compensation expense related to stock options for the nine months ended September 30, 2018 and 2017 was $95,000 and $276,000, respectively.   Restricted Stock Units   In addition to options to purchase shares of common stock, the Company may also grant restricted stock units (“RSUs”). RSUs are generally subject to graded vesting and the satisfaction of service requirements, similar to our stock options. Upon vesting, each outstanding RSU will be exchanged for one share of the Company’s common stock. The fair value of the RSUs awarded are based on the Company’s closing stock price at the grant date and are expensed over the requisite service period.   The following table summarizes the activity of the Company’s RSUs for the nine months ended September 30, 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted- Average Grant Date Fair Value Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left"> </td><td style="text-align: left">Unvested units at December 31, 2017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 1%; text-align: left"> </td><td style="width: 64%; text-align: left">Granted</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">151,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">1.79</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left"> </td><td style="text-align: left">Vested</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: left">Forfeited</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: left">Unvested units at September 30, 2018</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">151,250</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.79</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   During the three and nine months ended September 30, 2018, the Company recorded $22,000 of expense related to RSUs. There was no expense related to RSUs recorded in the same prior year periods. Such expense is included in stock-based compensation expense in the condensed consolidated statement of operations.   Restricted Stock   On August 31, 2018, Geert Cauwenbergh, Dr. Med. Sc., the Company’s Chief Executive Officer, elected the right to receive, in lieu of cash, for the period from September 15, 2018 to December 31, 2018, up to 50% of his base salary and cash bonuses, if any, (collectively, the “Compensation”) payable in the form of unvested, restricted shares of the Company’s common stock. Such restricted shares will be received in the form of a series of grants made on each Company payroll date in lieu of cash payment of the Compensation and shall vest in full on January 1, 2019, subject to his continued employment through such date. The fair value of the restricted stock is based on the Company’s closing stock price on the date of grant and is expensed over the vesting period.   For the three and nine months ended September 30, 2018, the Company granted 73,587 restricted shares of the Company’s common stock in lieu of Compensation to Dr. Cauwenbergh. No stock-based compensation expense was recorded related to the restricted shares for the three and nine months ended September 30, 2018 or 2017. Stock-based compensation expense based on the grant date fair value of the restricted shares will be recognized as an expense over the requisite vesting period, which is expected to occur during the three months ended December 31, 2018.   Compensation Expense Related to Equity Awards   The Company recorded total stock-based compensation expense related to equity awards in the condensed consolidated statement of operations for the three and nine months ended September 30, 2018 and 2017 as follows, in thousands:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">9</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">29</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">80</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">36</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">88</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">196</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 11pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">39</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">43</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">117</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">276</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted- Average Exercise Price Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 1%; text-align: left"> </td><td style="width: 53%; text-align: left">Balance at December 31, 2017</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">50,180</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">192.30</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">  </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left"> </td><td style="text-align: left">Exercised</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: left">Cancelled</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(916</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">29.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: left">Balance at September 30, 2018</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">157,514</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">62.35</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: left">Exercisable at September 30, 2018</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">38,939</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">244.14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

EX-101.SCH 5 rxii-20180930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - 1. Nature of Operations link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 2. Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 3. Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 4. Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 5. Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 6. Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 7. Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 2. Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 4. Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 5. Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 6. Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 1. Nature of Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 4. Stockholders' Equity (Details - Warrants outstanding) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 4. Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 5. Net Loss per Share (Details - Antidilutive shares) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 6. Stock-based Compensation (Details - Assumptions) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 6. Stock-based Compensation (Details - Option activity) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 6. Stock-based Compensation (Details - RSU activity) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 6. Stock-based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 7. Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 rxii-20180930_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 rxii-20180930_def.xml XBRL DEFINITION FILE EX-101.LAB 8 rxii-20180930_lab.xml XBRL LABEL FILE Income Statement Location [Axis] Research and Development Expense [Member] Sale of Stock [Axis] LPC Purchase Agreement [Member] April 2018 Direct Offering [Member] Class of Stock [Axis] Common Stock [Member] April 2018 Offering and Private Placement [Member] April 2018 Private Placement [Member] Warrants [Member] Counterparty Name [Axis] H.C. Wainwright [Member] Exercise Price Range [Axis] $52.00 [Member] $9.00 [Member] $3.15 [Member] $4.0546 [Member] Antidilutive Securities [Axis] Options [Member] Award Type [Axis] General and Administrative Expense [Member] Series B Preferred Stock [Member] Series C Preferred Stock [Member] Range [Axis] Minimum [Member] Maximum [Member] Restricted Stock Units (RSUs) [Member] Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Related Party [Axis] Cauwenbergh [Member] Restricted Stock [Member] Subsequent Event Type [Axis] Subsequent Event [Member] October 2018 Offering [Member] Financial Instrument [Axis] Units [Member] H.C. Wainwright & Co [Member] Securities Financing Transaction [Axis] Pre-Funded Units [Member] October 2018 Warrants [Member] Pre-Funded Warrants [Member] Shareholders' Equity Class [Axis] Document And Entity Information [Abstract] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Trading Symbol Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Entity Small Business Entity Emerging Growth Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Restricted cash Prepaid expenses and other current assets Total current assets Property and equipment, net Other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses Total current liabilities Commitments and contingencies Stockholders' equity: Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding Common stock, $0.0001 par value, 100,000,000 shares authorized; 4,449,909 and 2,429,993 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, par value Preferred stock, shares authorized Preferred Stock, shares issued Preferred Stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Operating expenses: Research and development Acquired in-process research and development General and administrative Total operating expenses Operating loss Total other expense, net Loss before income taxes Income tax benefit Net loss Net loss per share: Basic and diluted Weighted average shares: basic and diluted Statement [Table] Statement [Line Items] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Non-cash stock-based compensation Deferred taxes Changes in operating assets and liabilities: Prepaid expenses and other assets Accounts payable Accrued expenses Net cash used in operating activities Cash flows from investing activities: Cash acquired in MirImmune Inc. acquisition Cash paid for purchase of property and equipment Net cash provided by investing activities Cash flows from financing activities: Net proceeds from the issuance of common stock and warrants Net cash provided by (used in) financing activities Net increase (decrease) in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at the beginning of period Cash, cash equivalents and restricted cash at the end of period Supplemental disclosure of non-cash investing and financing activities: Conversions of convertible preferred stock into common stock Cancellation of notes receivable Accounts payable assumed Fair value of securities issued Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Operations Accounting Policies [Abstract] Significant Accounting Policies New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Recent Accounting Pronouncements Equity [Abstract] Stockholders' Equity Earnings Per Share [Abstract] Net Loss per Share Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock-based Compensation Subsequent Events [Abstract] Subsequent Events Basis of Presentation Principles of Consolidation Uses of Estimates in Preparation of Financial Statements Cash Equivalents and Restricted Cash Fair Value of Financial Instruments Research and Development Expenses Stock-based Compensation Income Taxes Comprehensive Loss Net Loss per Share Summary of outstanding warrants Schedule of antidilutive stock Schedule of Assumptions Used to Determine Fair Value of Option Grants Summary of Stock Option Activity Summary of RSU activity Details of Stock-based Compensation Expense Recorded Stock split description Reverse stock split ratio Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Exercise price Number of Shares Underlying Warrants Warrant expiration date Stock issued during period, shares Proceeds from the issuance of common stock Number of common stock issued upon conversion of convertible instrument Stock price per share Warrants issued Warrant exercise price Proceeds from the sale of equity Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total amount of anti-dilutive securities excluded from computation of earnings per share Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Risk-free interest rate, Minimum Risk-free interest rate, Maximum Risk-free interest rate Expected volatility, Minimum Expected volatility, Maximum Expected volatility Weighted average expected volatility Expected lives (in years) Expected dividend yield Number of Options Total Number of Shares, Beginning Balance Total Number of Shares, Granted Total Number of Shares, Exercised Total Number of Shares, Cancelled Total Number of Shares, Ending Balance Total Number of Shares, Exercisable EX-101.PRE 9 rxii-20180930_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Nov. 09, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Trading Symbol	RXII
Entity Registrant Name	RXi Pharmaceuticals Corp
Entity Central Index Key	0001533040
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		18,164,356
Entity Small Business	true
Entity Emerging Growth	false

XML 11 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 3,240	$ 3,581
Restricted cash	50	50
Prepaid expenses and other current assets	332	201
Total current assets	3,622	3,832
Property and equipment, net	187	248
Other assets	0	18
Total assets	3,809	4,098
Current liabilities:
Accounts payable	491	511
Accrued expenses	1,568	1,754
Total current liabilities	2,059	2,265
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.0001 par value, 100,000,000 shares authorized; 4,449,909 and 2,429,993 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	0	0
Additional paid-in capital	85,934	80,384
Accumulated deficit	(84,184)	(78,551)
Total stockholders' equity	1,750	1,833
Total liabilities and stockholders' equity	$ 3,809	$ 4,098

XML 12 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	4,449,909	2,429,993
Common stock, shares outstanding	4,449,909	2,429,993

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Revenues	$ 57	$ 0	$ 138	$ 0
Operating expenses:
Research and development	838	1,490	3,382	4,166
Acquired in-process research and development	0	0	0	4,696
General and administrative	711	986	2,386	3,209
Total operating expenses	1,549	2,476	5,768	12,071
Operating loss	(1,492)	(2,476)	(5,630)	(12,071)
Total other expense, net	(1)	0	(3)	0
Loss before income taxes	(1,493)	(2,476)	(5,633)	(12,071)
Income tax benefit	0	0	0	1,621
Net loss	$ (1,493)	$ (2,476)	$ (5,633)	$ (10,450)
Net loss per share: Basic and diluted	$ (0.34)	$ (1.05)	$ (1.54)	$ (4.71)
Weighted average shares: basic and diluted	4,371,259	2,351,144	3,662,924	2,216,775

XML 14 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (5,633)	$ (10,450)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	61	48
Non-cash stock-based compensation	117	276
Acquired in-process research and development	0	4,696
Deferred taxes	0	(1,621)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(113)	(121)
Accounts payable	(20)	(417)
Accrued expenses	(186)	276
Net cash used in operating activities	(5,774)	(7,313)
Cash flows from investing activities:
Cash acquired in MirImmune Inc. acquisition	0	100
Cash paid for purchase of property and equipment	0	(203)
Net cash provided by investing activities	0	(103)
Cash flows from financing activities:
Net proceeds from the issuance of common stock and warrants	5,433	(74)
Net cash provided by (used in) financing activities	5,433	(74)
Net increase (decrease) in cash, cash equivalents and restricted cash	(341)	(7,490)
Cash, cash equivalents and restricted cash at the beginning of period	3,631	12,956
Cash, cash equivalents and restricted cash at the end of period	3,290	5,466
Supplemental disclosure of non-cash investing and financing activities:
Cancellation of notes receivable	0	150
Accounts payable assumed	0	5
Fair value of securities issued	0	2,824
Series B Preferred Stock [Member]
Supplemental disclosure of non-cash investing and financing activities:
Conversions of convertible preferred stock into common stock	0	3,525
Series C Preferred Stock [Member]
Supplemental disclosure of non-cash investing and financing activities:
Conversions of convertible preferred stock into common stock	$ 0	$ 816

XML 15 R6.htm IDEA: XBRL DOCUMENT

1. Nature of Operations

9 Months Ended

Sep. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations

1. Nature of Operations

XML 16 R7.htm IDEA: XBRL DOCUMENT

2. Significant Accounting Policies

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Significant Accounting Policies

2. Significant Accounting Policies

Basis of Presentation

Principles of Consolidation

Uses of Estimates in Preparation of Financial Statements

Cash Equivalents and Restricted Cash

Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards.

Fair Value of Financial Instruments

The carrying amounts reported in the balance sheet for cash equivalents, restricted cash, accounts payable and accrued expenses approximate their fair values due to their short-term nature.

Research and Development Expenses

Stock-based Compensation

Income Taxes

Comprehensive Loss

The Company’s comprehensive loss is equal to its net loss for all periods presented.

Net Loss per Share

XML 17 R8.htm IDEA: XBRL DOCUMENT

3. Recent Accounting Pronouncements

9 Months Ended

Sep. 30, 2018

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Recent Accounting Pronouncements

3. Recent Accounting Pronouncements

XML 18 R9.htm IDEA: XBRL DOCUMENT

4. Stockholders' Equity

9 Months Ended

Sep. 30, 2018

Equity [Abstract]

Stockholders' Equity

4. Stockholders’ Equity

Warrants — The following table summarizes the Company’s outstanding equity-classified warrants at September 30, 2018:

Exercise price		Number of Shares Underlying Warrants		Expiration
$	52.00		130,007		June 2, 2020
$	9.00		1,277,793		December 21, 2021
$	3.15		1,132,953		May 31, 2023
$	4.0546		75,530		April 9, 2023
	Total warrants outstanding		2,616,283

XML 19 R10.htm IDEA: XBRL DOCUMENT

5. Net Loss per Share

9 Months Ended

Sep. 30, 2018

Earnings Per Share [Abstract]

Net Loss per Share

5. Net Loss per Share

The following table sets forth the potential common shares excluded from the calculation of net loss per share because their inclusion would be anti-dilutive:

	September 30,
	2018		2017
Options to purchase common stock		157,514		53,100
Unvested, restricted stock		73,587		–
Restricted stock units		151,250		–
Warrants to purchase common stock		2,616,283		1,408,000
Total		2,998,634		1,461,100

XML 20 R11.htm IDEA: XBRL DOCUMENT

6. Stock-based Compensation

9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-based Compensation

6. Stock-based Compensation

Stock Options

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2018			2017			2018			2017
Risk-free interest rate		2.93	%		1.94 – 2.35	%		2.70 – 2.93	%		1.73 – 2.49	%
Expected volatility		161.45	%		83.87 – 91.99	%		91.28 – 161.45	%		82.99 – 123.01	%
Weighted average expected volatility		161.45	%		87.93	%		159.55	%		84.65	%
Expected lives (in years)		6.25			6.25 – 10.00			5.50 – 10.00			5.20 – 10.00
Expected dividend yield		0.00	%		0.00	%		0.00	%		0.00	%

The following table summarizes the activity of the Company’s stock options for the nine months ended September 30, 2018:

	Number of Shares			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
Balance at December 31, 2017		50,180		$	192.30
Granted		108,250			1.83
Exercised		–			–
Cancelled		(916	)		29.50
Balance at September 30, 2018		157,514		$	62.35	$	–
Exercisable at September 30, 2018		38,939		$	244.14	$	–

Stock-based compensation expense related to stock options for the three months ended September 30, 2018 and 2017 was $17,000 and $43,000, respectively.

Stock-based compensation expense related to stock options for the nine months ended September 30, 2018 and 2017 was $95,000 and $276,000, respectively.

Restricted Stock Units

The following table summarizes the activity of the Company’s RSUs for the nine months ended September 30, 2018:

	Number of Shares		Weighted- Average Grant Date Fair Value Per Share
Unvested units at December 31, 2017		–	$	–
Granted		151,250		1.79
Vested		–		–
Forfeited		–		–
Unvested units at September 30, 2018		151,250	$	1.79

Restricted Stock

Compensation Expense Related to Equity Awards

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2018		2017		2018		2017
Research and development	$	9	$	7	$	29	$	80
General and administrative		30		36		88		196
Total stock-based compensation	$	39	$	43	$	117	$	276

XML 21 R12.htm IDEA: XBRL DOCUMENT

7. Subsequent Events

9 Months Ended

Sep. 30, 2018

Subsequent Events [Abstract]

Subsequent Events

7. Subsequent Events

The net proceeds from the October 2018 Offering will be reflected in stockholders’ equity for the year ending December 31, 2018.

Subsequent to the balance sheet date, 10,534,286 Pre-Funded Warrants were converted into 10,534,286 shares of common stock for net proceeds of $105,000.

XML 22 R13.htm IDEA: XBRL DOCUMENT

2. Significant Accounting Policies (Policies)	9 Months Ended
2. Significant Accounting Policies (Policies)	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Certain information and footnote disclosures included in the Company’s annual financial statements have been condensed or omitted. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included. Interim results are not necessarily indicative of results for a full year.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of RXi Pharmaceuticals Corporation and its wholly-owned subsidiary, MirImmune, LLC. All material intercompany accounts have been eliminated in consolidation.
Uses of Estimates in Preparation of Financial Statements	Uses of Estimates in Preparation of Financial Statements The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from these estimates.
Cash Equivalents and Restricted Cash	Cash Equivalents and Restricted Cash The Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in certificates of deposit. Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for cash equivalents, restricted cash, accounts payable and accrued expenses approximate their fair values due to their short-term nature.
Research and Development Expenses	Research and Development Expenses Research and development costs relate to salaries, employee benefits, facility-related expenses, supplies, stock-based compensation related to employees and non-employees involved in the Company’s research and development, external services, other operating costs and overhead related to its research and development departments, costs to acquire technology licenses and expenses associated with preclinical activities and its clinical trials. Research and development expenses are charged to expense as incurred. Payments made by the Company in advance for research and development services not yet provided and/or for materials not yet received are recorded as prepaid expenses and expensed when the service has been performed or when the goods have been received. Accrued liabilities are recorded related to those expenses for which vendors have not yet billed the Company with respect to services provided and/or materials that it has received. Preclinical and clinical trial expenses relate to estimates of costs incurred and fees connected with clinical trial sites, third-party clinical research organizations and other preclinical and clinical related activities and include such items as subject-related fees, laboratory work, investigator fees and analysis costs. Costs associated with these expenses are generally payable on the passage of time or when certain milestones are achieved. Expense is recorded during the period incurred or in the period in which a milestone is achieved. In order to ensure that the Company has adequately provided for preclinical and clinical expenses during the proper period, the Company maintains an accrual to cover these expenses. These accruals are assessed on a quarterly basis and are based on such assumptions as expected total cost, the length of the study, timing of certain milestones and other information available to us. Actual results may differ from these estimates and could have a material impact on the Company’s reported results. The Company’s historical accrual estimates have not been materially different from its actual costs.
Stock-based Compensation	Stock-based Compensation The Company follows the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, “Compensation — Stock Compensation” (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, officers, non-employee directors, and non-employees, including stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period.
Income Taxes	Income Taxes The Company recognizes assets or liabilities for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with the FASB ASC Topic 740, “Accounting for Income Taxes.” On December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act tax reform legislation. This legislation makes significant changes in U.S. tax law including a reduction in the corporate tax rates, changes to net operating loss carryforwards and carrybacks, and a repeal of the corporate alternative minimum tax. The Company is continuing to assess the impact of the Tax Cuts and Jobs Act and does not expect the provisions to have a material impact on the Company’s consolidated financial statements.
Comprehensive Loss	Comprehensive Loss The Company’s comprehensive loss is equal to its net loss for all periods presented.
Net Loss per Share	Net Loss per Share The Company accounts for and discloses net loss per share in accordance with the FASB ASC Topic 260, “Earnings per Share.” Basic and diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares.

XML 23 R14.htm IDEA: XBRL DOCUMENT

4. Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2018

Equity [Abstract]

Summary of outstanding warrants

Exercise price		Number of Shares Underlying Warrants		Expiration
$	52.00		130,007		June 2, 2020
$	9.00		1,277,793		December 21, 2021
$	3.15		1,132,953		May 31, 2023
$	4.0546		75,530		April 9, 2023
	Total warrants outstanding		2,616,283

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 24 R15.htm IDEA: XBRL DOCUMENT

5. Net Loss per Share (Tables)

9 Months Ended

Sep. 30, 2018

Earnings Per Share [Abstract]

Schedule of antidilutive stock

	September 30,
	2018		2017
Options to purchase common stock		157,514		53,100
Unvested, restricted stock		73,587		–
Restricted stock units		151,250		–
Warrants to purchase common stock		2,616,283		1,408,000
Total		2,998,634		1,461,100

XML 25 R16.htm IDEA: XBRL DOCUMENT

6. Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Assumptions Used to Determine Fair Value of Option Grants

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2018			2017			2018			2017
Risk-free interest rate		2.93	%		1.94 – 2.35	%		2.70 – 2.93	%		1.73 – 2.49	%
Expected volatility		161.45	%		83.87 – 91.99	%		91.28 – 161.45	%		82.99 – 123.01	%
Weighted average expected volatility		161.45	%		87.93	%		159.55	%		84.65	%
Expected lives (in years)		6.25			6.25 – 10.00			5.50 – 10.00			5.20 – 10.00
Expected dividend yield		0.00	%		0.00	%		0.00	%		0.00	%

Summary of Stock Option Activity

	Number of Shares			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
Balance at December 31, 2017		50,180		$	192.30
Granted		108,250			1.83
Exercised		–			–
Cancelled		(916	)		29.50
Balance at September 30, 2018		157,514		$	62.35	$	–
Exercisable at September 30, 2018		38,939		$	244.14	$	–

Summary of RSU activity

	Number of Shares		Weighted- Average Grant Date Fair Value Per Share
Unvested units at December 31, 2017		–	$	–
Granted		151,250		1.79
Vested		–		–
Forfeited		–		–
Unvested units at September 30, 2018		151,250	$	1.79

Details of Stock-based Compensation Expense Recorded

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2018		2017		2018		2017
Research and development	$	9	$	7	$	29	$	80
General and administrative		30		36		88		196
Total stock-based compensation	$	39	$	43	$	117	$	276

XML 26 R17.htm IDEA: XBRL DOCUMENT

1. Nature of Operations (Details Narrative)	Jan. 03, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Stock split description	Company approved a 1-for-10 reverse stock split of the Company’s outstanding common stock, which was effected on January 8, 2018.
Reverse stock split ratio	.001

XML 27 R18.htm IDEA: XBRL DOCUMENT

4. Stockholders' Equity (Details - Warrants outstanding) - Warrants [Member]	9 Months Ended
	Sep. 30, 2018 $ / shares shares
Class of Warrant or Right [Line Items]
Number of Shares Underlying Warrants	2,616,283
$52.00 [Member]
Class of Warrant or Right [Line Items]
Exercise price \| $ / shares	$ 52.00
Number of Shares Underlying Warrants	130,007
Warrant expiration date	Jun. 02, 2020
$9.00 [Member]
Class of Warrant or Right [Line Items]
Exercise price \| $ / shares	$ 9.00
Number of Shares Underlying Warrants	1,277,793
Warrant expiration date	Dec. 21, 2021
$3.15 [Member]
Class of Warrant or Right [Line Items]
Exercise price \| $ / shares	$ 3.15
Number of Shares Underlying Warrants	1,132,953
Warrant expiration date	May 31, 2023
$4.0546 [Member]
Class of Warrant or Right [Line Items]
Exercise price \| $ / shares	$ 4.0546
Number of Shares Underlying Warrants	75,530
Warrant expiration date	Apr. 09, 2023

XML 28 R19.htm IDEA: XBRL DOCUMENT

4. Stockholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Apr. 11, 2018
Proceeds from the sale of equity		$ 5,433	$ (74)
LPC Purchase Agreement [Member]
Stock issued during period, shares	15,000	435,000
Proceeds from the issuance of common stock	$ 21	$ 1,312
April 2018 Direct Offering [Member] \| Common Stock [Member]
Stock issued during period, shares		1,510,604
Stock price per share				$ 3.15
April 2018 Private Placement [Member] \| Warrants [Member]
Stock price per share				$ 0.125
Warrants issued				1,132,953
Warrant exercise price				$ 3.15
April 2018 Offering and Private Placement [Member]
Proceeds from the sale of equity		$ 4,210
April 2018 Offering and Private Placement [Member] \| H.C. Wainwright [Member]
Warrants issued				75,530
Warrant exercise price				$ 4.0546

XML 29 R20.htm IDEA: XBRL DOCUMENT

5. Net Loss per Share (Details - Antidilutive shares) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total amount of anti-dilutive securities excluded from computation of earnings per share	2,998,634	1,461,100
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total amount of anti-dilutive securities excluded from computation of earnings per share	157,514	53,100
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total amount of anti-dilutive securities excluded from computation of earnings per share	73,587	0
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total amount of anti-dilutive securities excluded from computation of earnings per share	151,250	0
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total amount of anti-dilutive securities excluded from computation of earnings per share	2,616,283	1,408,000

XML 30 R21.htm IDEA: XBRL DOCUMENT

6. Stock-based Compensation (Details - Assumptions)	3 Months Ended		9 Months Ended
6. Stock-based Compensation (Details - Assumptions)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, Minimum		1.94%	2.70%	1.73%
Risk-free interest rate, Maximum		2.35%	2.93%	2.49%
Risk-free interest rate	2.93%
Expected volatility, Minimum		83.87%	91.28%	82.99%
Expected volatility, Maximum		91.99%	161.45%	123.01%
Expected volatility	161.45%
Weighted average expected volatility	161.45%	87.93%	159.55%	84.65%
Expected lives (in years)	6 years 3 months
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected lives (in years)		6 years 3 months	5 years 6 months	5 years 2 months 12 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected lives (in years)		10 years	10 years	10 years

XML 31 R22.htm IDEA: XBRL DOCUMENT

6. Stock-based Compensation (Details - Option activity) - Options [Member] $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2018 USD ($) $ / shares shares
Number of Options
Total Number of Shares, Beginning Balance \| shares	50,180
Total Number of Shares, Granted \| shares	108,250
Total Number of Shares, Exercised \| shares	0
Total Number of Shares, Cancelled \| shares	(916)
Total Number of Shares, Ending Balance \| shares	157,514
Total Number of Shares, Exercisable \| shares	38,939
Weighted-Average Exercise Price
Weighted-Average Exercise Price Per Share, Beginning Balance \| $ / shares	$ 192.30
Weighted-Average Exercise Price Per Share, Granted \| $ / shares	1.83
Weighted-Average Exercise Price Per Share, Exercised \| $ / shares
Weighted-Average Exercise Price Per Share, Cancelled \| $ / shares	29.50
Weighted-Average Exercise Price Per Share, Ending Balance \| $ / shares	62.35
Weighted-Average Exercise Price Per Share, Exercisable \| $ / shares	$ 244.14
Aggregate Intrinsic Value
Aggregate Intrinsic Value, Ending Balance \| $	$ 0
Aggregate Intrinsic Value, Exercisable \| $	$ 0

XML 32 R23.htm IDEA: XBRL DOCUMENT

6. Stock-based Compensation (Details - RSU activity) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2018 $ / shares shares
RSU's unvested units, beginning balance \| shares	0
RSU's granted \| shares	151,250
RSU's vested \| shares	0
RSU's forfeited \| shares	0
RSU's unvested units, ending balance \| shares	151,250
RSU beginning grant date price per share \| $ / shares	$ 0
RSU's granted, price per share \| $ / shares	1.79
RSU's vested, price per share \| $ / shares
RSU's forfeited, price per share \| $ / shares
RSU's ending price per share \| $ / shares	$ 1.79

XML 33 R24.htm IDEA: XBRL DOCUMENT

6. Stock-based Compensation (Details - Share-based compensation) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 39	$ 43	$ 117	$ 276
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	9	7	29	80
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 30	$ 36	$ 88	$ 196

XML 34 R25.htm IDEA: XBRL DOCUMENT

6. Stock-based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based compensation expense	$ 39	$ 43	$ 117	$ 276
Cauwenbergh [Member] \| Restricted Stock [Member]
Share-based compensation expense	$ 0	$ 0	$ 0	$ 0
Restricted stock granted for compensation, shares	73,587		73,587
Options [Member]
Weighted average grant date fair value per share of options granted	$ 1.72	$ 4.90	$ 1.75	$ 4.90
Share-based compensation expense	$ 17	$ 43	$ 95	$ 276
Restricted Stock Units (RSUs) [Member]
Share-based compensation expense	$ 22	$ 0	$ 22	$ 0

XML 35 R26.htm IDEA: XBRL DOCUMENT

7. Subsequent Events (Details Narrative) - USD ($)	9 Months Ended			10 Months Ended
7. Subsequent Events (Details Narrative) - USD ($)	Oct. 03, 2018	Sep. 30, 2018	Sep. 30, 2017	Nov. 05, 2018
Proceeds from sale of equity		$ 5,433,000	$ (74,000)
Subsequent Event [Member] \| Pre-Funded Warrants [Member] \| Common Stock [Member]
Pre-Funded Warrants converted				10,534,286
Stock issued upon conversion of pre-funded warrants				10,534,286
Proceeds from conversionof pre-funded warrants				$ 105,000
Subsequent Event [Member] \| October 2018 Offering [Member]
Proceeds from sale of equity	$ 13,300,000
Subsequent Event [Member] \| October 2018 Offering [Member] \| H.C. Wainwright & Co [Member]
Warrants isssued new, shares	1,607,143
Warrant exercise price	$ 0.875
Subsequent Event [Member] \| October 2018 Offering [Member] \| Pre-Funded Units [Member]
Pre-funded unit description	One pre-funded warrant and one warrant
Pre-funded warrants issued new, shares	17,702,858
Shares issued price per share	$ 0.69
Subsequent Event [Member] \| October 2018 Offering [Member] \| Units [Member]
Unit description	One share of common stock and one warrant
Stock issued new, shares	3,725,714
Warrants isssued new, shares	3,725,714
Shares issued price per share	$ 0.70
Warrant exercise price	0.70
Subsequent Event [Member] \| October 2018 Offering [Member] \| October 2018 Warrants [Member]
Warrant exercise price	$ 0.70
Warrant expiration term	7 years
Subsequent Event [Member] \| October 2018 Offering [Member] \| Pre-Funded Warrants [Member] \| Pre-Funded Units [Member]
Pre-funded warrant description	Convertible into one share of common stock
Warrant exercise price	$ 0.01

EXCEL 36 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 38 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 40 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 81 141 1 false 34 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://rxipharma.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://rxipharma.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://rxipharma.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://rxipharma.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://rxipharma.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - 1. Nature of Operations Sheet http://rxipharma.com/role/NatureOfOperations 1. Nature of Operations Notes 6 false false R7.htm 00000007 - Disclosure - 2. Significant Accounting Policies Sheet http://rxipharma.com/role/SignificantAccountingPolicies 2. Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - 3. Recent Accounting Pronouncements Sheet http://rxipharma.com/role/RecentAccountingPronouncements 3. Recent Accounting Pronouncements Notes 8 false false R9.htm 00000009 - Disclosure - 4. Stockholders' Equity Sheet http://rxipharma.com/role/StockholdersEquity 4. Stockholders' Equity Notes 9 false false R10.htm 00000010 - Disclosure - 5. Net Loss per Share Sheet http://rxipharma.com/role/NetLossPerShare 5. Net Loss per Share Notes 10 false false R11.htm 00000011 - Disclosure - 6. Stock-based Compensation Sheet http://rxipharma.com/role/Stock-basedCompensation 6. Stock-based Compensation Notes 11 false false R12.htm 00000012 - Disclosure - 7. Subsequent Events Sheet http://rxipharma.com/role/SubsequentEvents 7. Subsequent Events Notes 12 false false R13.htm 00000013 - Disclosure - 2. Significant Accounting Policies (Policies) Sheet http://rxipharma.com/role/SignificantAccountingPoliciesPolicies 2. Significant Accounting Policies (Policies) Policies http://rxipharma.com/role/SignificantAccountingPolicies 13 false false R14.htm 00000014 - Disclosure - 4. Stockholders' Equity (Tables) Sheet http://rxipharma.com/role/StockholdersEquityTables 4. Stockholders' Equity (Tables) Tables http://rxipharma.com/role/StockholdersEquity 14 false false R15.htm 00000015 - Disclosure - 5. Net Loss per Share (Tables) Sheet http://rxipharma.com/role/NetLossPerShareTables 5. Net Loss per Share (Tables) Tables http://rxipharma.com/role/NetLossPerShare 15 false false R16.htm 00000016 - Disclosure - 6. Stock-based Compensation (Tables) Sheet http://rxipharma.com/role/Stock-basedCompensationTables 6. Stock-based Compensation (Tables) Tables http://rxipharma.com/role/Stock-basedCompensation 16 false false R17.htm 00000017 - Disclosure - 1. Nature of Operations (Details Narrative) Sheet http://rxipharma.com/role/NatureOfOperationsDetailsNarrative 1. Nature of Operations (Details Narrative) Details http://rxipharma.com/role/NatureOfOperations 17 false false R18.htm 00000018 - Disclosure - 4. Stockholders' Equity (Details - Warrants outstanding) Sheet http://rxipharma.com/role/StockholdersEquityDetails-WarrantsOutstanding 4. Stockholders' Equity (Details - Warrants outstanding) Details http://rxipharma.com/role/StockholdersEquityTables 18 false false R19.htm 00000019 - Disclosure - 4. Stockholders' Equity (Details Narrative) Sheet http://rxipharma.com/role/StockholdersEquityDetailsNarrative 4. Stockholders' Equity (Details Narrative) Details http://rxipharma.com/role/StockholdersEquityTables 19 false false R20.htm 00000020 - Disclosure - 5. Net Loss per Share (Details - Antidilutive shares) Sheet http://rxipharma.com/role/NetLossPerShareDetails-AntidilutiveShares 5. Net Loss per Share (Details - Antidilutive shares) Details http://rxipharma.com/role/NetLossPerShareTables 20 false false R21.htm 00000021 - Disclosure - 6. Stock-based Compensation (Details - Assumptions) Sheet http://rxipharma.com/role/Stock-basedCompensationDetails-Assumptions 6. Stock-based Compensation (Details - Assumptions) Details http://rxipharma.com/role/Stock-basedCompensationTables 21 false false R22.htm 00000022 - Disclosure - 6. Stock-based Compensation (Details - Option activity) Sheet http://rxipharma.com/role/Stock-basedCompensationDetails-OptionActivity 6. Stock-based Compensation (Details - Option activity) Details http://rxipharma.com/role/Stock-basedCompensationTables 22 false false R23.htm 00000023 - Disclosure - 6. Stock-based Compensation (Details - RSU activity) Sheet http://rxipharma.com/role/Stock-basedCompensationDetails-RsuActivity 6. Stock-based Compensation (Details - RSU activity) Details http://rxipharma.com/role/Stock-basedCompensationTables 23 false false R24.htm 00000024 - Disclosure - 6. Stock-based Compensation (Details - Share-based compensation) Sheet http://rxipharma.com/role/Stock-basedCompensationDetails-Share-basedCompensation 6. Stock-based Compensation (Details - Share-based compensation) Details http://rxipharma.com/role/Stock-basedCompensationTables 24 false false R25.htm 00000025 - Disclosure - 6. Stock-based Compensation (Details Narrative) Sheet http://rxipharma.com/role/Stock-basedCompensationDetailsNarrative 6. Stock-based Compensation (Details Narrative) Details http://rxipharma.com/role/Stock-basedCompensationTables 25 false false R26.htm 00000026 - Disclosure - 7. Subsequent Events (Details Narrative) Sheet http://rxipharma.com/role/SubsequentEventsDetailsNarrative 7. Subsequent Events (Details Narrative) Details http://rxipharma.com/role/SubsequentEvents 26 false false All Reports Book All Reports rxii-20180930.xml rxii-20180930.xsd rxii-20180930_cal.xml rxii-20180930_def.xml rxii-20180930_lab.xml rxii-20180930_pre.xml http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 42 0001683168-18-003390-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-18-003390-xbrl.zip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�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end

6. Stock-based Compensation (Details - RSU activity) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2018 $ / shares shares
RSU's unvested units, beginning balance \| shares	0
RSU's granted \| shares	151,250
RSU's vested \| shares	0
RSU's forfeited \| shares	0
RSU's unvested units, ending balance \| shares	151,250
RSU beginning grant date price per share \| $ / shares	$ 0
RSU's granted, price per share \| $ / shares	1.79
RSU's vested, price per share \| $ / shares
RSU's forfeited, price per share \| $ / shares
RSU's ending price per share \| $ / shares	$ 1.79

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company